Insulin Regular

<drug type="biotech" created="2005-06-13" updated="2013-06-27">
  <drugbank-id primary="true">DB00030</drugbank-id>
  <drugbank-id>BIOD00105</drugbank-id>
  <drugbank-id>BTD00105</drugbank-id>
  <drugbank-id>DB01383</drugbank-id>
  <name>Insulin Regular</name>
  <description>Insulin regular is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant DNA techncology. Inserting the human insulin gene into the Escherichia coli bacteria or Saccharomyces cerevisiae produces insulin for human use. </description>
  <cas-number>11061-68-0</cas-number>
  <groups>
    <group>approved</group>
    <group>experimental</group>
    <group>investigational</group>
  </groups>
  <general-references># Herrmann BL, Kasser C, Keuthage W, Huptas M, Dette H, Klute A: Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2013 Apr;121(4):210-3. doi: 10.1055/s-0033-1334905. Epub 2013 Mar 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23512415</general-references>
  <synthesis-reference>Humulin is synthesized in a special non-disease-producing laboratory strain of Escherichia coli bacteria that has been genetically altered to produce human insulin.</synthesis-reference>
  <indication>Indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus. </indication>
  <pharmacodynamics>Insulin regular is a short-acting insulin. When subcutaneously administered, the onset of action (as evidenced by a decrease in glucose level) occurs 30 minutes post-dose. Maximal effect occurs between 1.5 and 3.5 hours post-dose. The glucose-lowering effect occurs 8 hours post-dose. Compared to other rapid-acting insulin analogs, insulin regular has a slower onset of action and longer duration of action. </pharmacodynamics>
  <mechanism-of-action>The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.&#13;
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.</mechanism-of-action>
  <toxicity>Hypoglycemia is one of the most frequent adverse events experienced by insulin users. </toxicity>
  <metabolism>Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.</metabolism>
  <absorption>Insulin is generally well absorbed. </absorption>
  <half-life/>
  <protein-binding>5% protein bound </protein-binding>
  <route-of-elimination/>
  <volume-of-distribution>0.15 L/kg </volume-of-distribution>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Insulin human </synonym>
  </synonyms>
  <products>
    <product>
      <name>Afrezza</name>
      <ndc-id>0024-5874_f222a734-081c-4098-a973-a3274e29e7ac</ndc-id>
      <ndc-product-code>0024-5874</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>powder, metered</dosage-form>
      <strength>4 1</strength>
      <route>respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog 70/30</name>
      <ndc-id>54868-2746_3457b3b5-976d-4240-bfad-e448294ec9cb</ndc-id>
      <ndc-product-code>54868-2746</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1994-12-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 70/30</name>
      <ndc-id>0002-8715_003856b7-9100-4b23-bedb-3045b2e6f405</ndc-id>
      <ndc-product-code>0002-8715</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1989-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 70/30</name>
      <ndc-id>0002-8770_003856b7-9100-4b23-bedb-3045b2e6f405</ndc-id>
      <ndc-product-code>0002-8770</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-02-01</started-marketing-on>
      <ended-marketing-on>2015-10-31</ended-marketing-on>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 70/30</name>
      <ndc-id>0002-8803_003856b7-9100-4b23-bedb-3045b2e6f405</ndc-id>
      <ndc-product-code>0002-8803</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 70/30 70/30</name>
      <ndc-id>52125-415_4db2dc6a-a89e-497b-bc23-4f3d57e899f4</ndc-id>
      <ndc-product-code>52125-415</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 70/30 70/30</name>
      <ndc-id>52125-415_b1b49436-6e5c-4b36-8982-989d622f35ed</ndc-id>
      <ndc-product-code>52125-415</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin N</name>
      <ndc-id>0002-8730_ea9b211f-abbc-4a62-867a-596a24a5b419</ndc-id>
      <ndc-product-code>0002-8730</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-02-01</started-marketing-on>
      <ended-marketing-on>2015-10-31</ended-marketing-on>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA018781</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin N</name>
      <ndc-id>0002-8805_ea9b211f-abbc-4a62-867a-596a24a5b419</ndc-id>
      <ndc-product-code>0002-8805</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA018781</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin N</name>
      <ndc-id>54868-1429_2232ce07-e218-4907-8f20-1e8fe3277dde</ndc-id>
      <ndc-product-code>54868-1429</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1994-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA018781</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin R</name>
      <ndc-id>0002-8215_08827443-2aa4-4cd9-9657-64a52085fd83</ndc-id>
      <ndc-product-code>0002-8215</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1983-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>parenteral</route>
      <fda-application-number>NDA018780</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin R</name>
      <ndc-id>54868-3619_5ace7bf4-ae3d-4cc5-b5b6-a171d26d82a2</ndc-id>
      <ndc-product-code>54868-3619</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1995-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA018780</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin R U-500</name>
      <ndc-id>0002-8501_56852e9d-9832-4a7e-a19f-7ae855017bd6</ndc-id>
      <ndc-product-code>0002-8501</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1997-01-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, solution</dosage-form>
      <strength>500 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA018780</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <ndc-id>0169-1837_6748f022-4f9d-42ea-9f82-e39abad34324</ndc-id>
      <ndc-product-code>0169-1837</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [USP'U]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <ndc-id>54569-2918_8e7cb87c-79c5-46d0-88b7-5ccb6b66dd87</ndc-id>
      <ndc-product-code>54569-2918</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [USP'U]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <ndc-id>54868-3474_f8f7bdaf-47bb-43bc-8696-a6b844e21933</ndc-id>
      <ndc-product-code>54868-3474</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1995-01-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [USP'U]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <ndc-id>64725-1837_05dc7def-3137-4c5c-8d43-2baf9d7888df</ndc-id>
      <ndc-product-code>64725-1837</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [USP'U]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin N</name>
      <ndc-id>0169-1834_5ddfd50a-7a65-4658-85d6-500ae7aae946</ndc-id>
      <ndc-product-code>0169-1834</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin N</name>
      <ndc-id>64725-1834_88240c8b-10c5-43b4-8a36-020380cea930</ndc-id>
      <ndc-product-code>64725-1834</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <ndc-id>0169-1833_6ede8238-f902-478d-8cee-997855045083</ndc-id>
      <ndc-product-code>0169-1833</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <ndc-id>64725-1833_a2c745d7-1b63-4064-b6a1-e18e43b318ad</ndc-id>
      <ndc-product-code>64725-1833</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin70/30 70/30</name>
      <ndc-id>52125-414_4c714861-6964-4ecf-bf7e-2f353c9226c2</ndc-id>
      <ndc-product-code>52125-414</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [USP'U]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin70/30 70/30</name>
      <ndc-id>52125-414_ea917f6b-3e25-4236-93ae-9376d5282b27</ndc-id>
      <ndc-product-code>52125-414</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>injection, suspension</dosage-form>
      <strength>100 [USP'U]/mL</strength>
      <route>subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Humulin R</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R U-500</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Novolin N</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Novolin70/30 70/30</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Novolin70/30 70/30</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30 70/30</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30 70/30</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Humalog 70/30</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Novolin N</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin Regular</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>DispenseXpress Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Eli Lilly &amp; Co.</name>
      <url>http://www.lilly.com</url>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Intervet International</name>
      <url>http://www.intervet.ca</url>
    </packager>
    <packager>
      <name>Novo Nordisk Inc.</name>
      <url>http://www.novonordisk.com</url>
    </packager>
    <packager>
      <name>Pfizer Inc.</name>
      <url>http://www.pfizer.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false">Novo nordisk inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Novolin Ge Nph 100 unit/ml</description>
      <cost currency="USD">2.14</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Novolin Ge Toronto 100 unit/ml</description>
      <cost currency="USD">2.14</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humulin N 100 unit/ml</description>
      <cost currency="USD">2.29</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humulin R 100 unit/ml</description>
      <cost currency="USD">2.29</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Novolin Ge Nph Penfill 100 unit/ml Cartridge</description>
      <cost currency="USD">2.78</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Novolin Ge Toronto Penfill 100 unit/ml Cartridge</description>
      <cost currency="USD">2.8</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humulin N Cartridge 100 unit/ml Cartridge</description>
      <cost currency="USD">2.99</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humulin R Cartridge 100 unit/ml Cartridge</description>
      <cost currency="USD">2.99</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>NovoLIN R InnoLet 100 unit/ml Solution 3ml Cartridge</description>
      <cost currency="USD">24.17</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Novolin r 100 unit/ml cartridg</description>
      <cost currency="USD">33.33</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>NovoLIN R 100 unit/ml Solution 10ml Vial</description>
      <cost currency="USD">73.19</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>NovoLIN R PenFill 100 unit/ml Solution Five 3ml Cartridges Per Box = 15ml</description>
      <cost currency="USD">162.26</cost>
      <unit>cartridge</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Antidiabetic Agents</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder, metered</form>
      <route>respiratory (inhalation)</route>
      <strength>4 1</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>subcutaneous</route>
      <strength>100 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>parenteral</route>
      <strength>100 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>subcutaneous</route>
      <strength>500 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>subcutaneous</route>
      <strength>100 [USP'U]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>subcutaneous</route>
      <strength>100 [iU]/mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>68:20.08</ahfs-code>
    <ahfs-code>92:02.00*</ahfs-code>
  </ahfs-codes>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09009</drugbank-id>
      <name>Articaine</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06719</drugbank-id>
      <name>Buserelin</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01406</drugbank-id>
      <name>Danazol</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02901</drugbank-id>
      <name>Dihydrotestosterone</name>
      <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic Acid</name>
      <description>May enhance the hypoglycemic effect of Insulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic Acid</name>
      <description>May enhance the hypoglycemic effect of Insulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estropipate</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Ethacrynic acid</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinyl Estradiol</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01319</drugbank-id>
      <name>Fosamprenavir</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06788</drugbank-id>
      <name>Histrelin</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05278</drugbank-id>
      <name>inhaled insulin</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin Aspart</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin Detemir</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin Glargine</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin Glulisine</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin Lispro</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08914</drugbank-id>
      <name>Insulin, isophane</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06791</drugbank-id>
      <name>Lanreotide</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00166</drugbank-id>
      <name>Lipoic Acid</name>
      <description>May enhance the hypoglycemic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>May enhance the hypoglycemic effect of Insulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01277</drugbank-id>
      <name>Mecasermin</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone Acetate</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09046</drugbank-id>
      <name>Metreleptin</name>
      <description>May enhance the hypoglycemic effect of Insulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00627</drugbank-id>
      <name>Niacin</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethindrone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00621</drugbank-id>
      <name>Oxandrolone</name>
      <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06663</drugbank-id>
      <name>Pasireotide</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>May enhance the adverse/toxic effect of Insulin. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00592</drugbank-id>
      <name>Piperazine</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>May enhance the hypoglycemic effect of Insulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Insulin may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01398</drugbank-id>
      <name>Salicylate-sodium</name>
      <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06825</drugbank-id>
      <name>Triptorelin</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;A chain
GIVEQCCTSICSLYQLENYCN</sequence>
    <sequence format="FASTA">&gt;B chain
FVNQHLCGSHLVEALYLVCGERGFFYTPKT</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>81 °C</value>
      <source>Khachidze, D.G. et al., J. Biol. Phys. Chem. 1:64-67 (2001)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>0.218</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.39</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>5808 Daltons </value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C257H383N65O77S6</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>5931</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C00723</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D03230</identifier>
    </external-identifier>
    <external-identifier>
      <resource>National Drug Code Directory</resource>
      <identifier>0002-8215-01</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>AY137503</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164744571</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>Q8HXV2</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Insulin</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/novolog.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/pro/humulin-r.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000033</id>
      <name>Insulin receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references># Desbuquois B, Chauvet G, Kouach M, Authier F: Cell itinerary and metabolic fate of proinsulin in rat liver: in vivo and in vitro studies. Endocrinology. 2003 Dec;144(12):5308-21. Epub 2003 Sep 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12970169&#13;
# Chen LM, Yang XW, Tang JG: Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem (Tokyo). 2002 Jun;131(6):855-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12038982&#13;
# Bell DS: Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised? Drugs. 2007;67(13):1813-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17722952&#13;
# Tanti JF, Jager J: Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol. 2009 Dec;9(6):753-62. Epub 2009 Aug 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19683471&#13;
# Chiu SL, Cline HT: Insulin receptor signaling in the development of neuronal structure and function. Neural Dev. 2010 Mar 15;5:7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20230616&#13;
# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
      <known-action>yes</known-action>
      <polypeptide id="P06213" source="Swiss-Prot">
    <name>Insulin receptor</name>
    <general-function>Involved in transmembrane receptor protein tyrosine kinase activity</general-function>
    <specific-function>This receptor binds insulin and has a tyrosine-protein kinase activity. Isoform Short has a higher affinity for insulin. Mediates the metabolic functions of insulin. Binding to insulin stimulates association of the receptor with downstream mediators including IRS1 and phosphatidylinositol 3'-kinase (PI3K). Can activate PI3K either directly by binding to the p85 regulatory subunit, or indirectly via IRS1</specific-function>
    <gene-name>INSR</gene-name>
    <locus>19p13.3-p13.2</locus>
    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
    <transmembrane-regions>957-979</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>6.18</theoretical-pi>
    <molecular-weight>156308.0</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6091</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>INSR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GeneCards</resource>
        <identifier>INSR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M10051</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>307070</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P06213</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INSR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD220 antigen</synonym>
      <synonym>EC 2.7.10.1</synonym>
      <synonym>Insulin receptor precursor</synonym>
      <synonym>IR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;Insulin receptor precursor
MGTGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL
QILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL
VIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE
ECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL
GNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG
CHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC
TVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL
EIGNYSFYALDNQNLRQLWDWSKHNLTTTQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE
RNDIALKTNGDKASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ
NVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS
DERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE
RQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL
KELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF
PNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV
SARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV
SRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG
PLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR
EKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG
FTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA
AEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV
RWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN
CPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME
FEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN
PS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;4149 bp
ATGGGCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG
CTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC
CGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG
CAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA
CTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG
GACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG
GTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC
CGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG
TCCCGTATCCTGGATTCCGTGGAGGATAATCACATCGTGTTGAACAAAGATGACAACGAG
GAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC
ATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG
ACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG
GGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG
GACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT
GTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC
TGCCACCAATACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG
ATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC
CTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC
ACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG
CTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC
TACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG
GAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC
TGGAGCAAACACAACCTCACCACCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA
CTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG
AGAAACGACATTGCCCTGAAGACCAATGGGGACAAGGCATCCTGTGAAAATGAGTTACTT
AAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG
CCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG
AATGTGACGGAGTTCGATGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC
ATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG
CGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG
GATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC
AACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG
AAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG
AGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG
CCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT
GAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG
AAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT
TTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA
CGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC
CCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG
GTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC
GAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC
AGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA
ATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG
ATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC
TCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC
TACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC
TATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC
CCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA
AAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC
AGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA
GAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC
AATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC
GAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC
TTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG
GTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA
GAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG
GCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG
GCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG
ACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA
CGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG
TCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG
TCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC
TGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG
CCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG
GTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG
TTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG
GGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT
TACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT
CCTTCCTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07714</identifier>
        <name>Pkinase_Tyr</name>
      </pfam>
      <pfam>
        <identifier>PF00041</identifier>
        <name>fn3</name>
      </pfam>
      <pfam>
        <identifier>PF00757</identifier>
        <name>Furin-like</name>
      </pfam>
      <pfam>
        <identifier>PF01030</identifier>
        <name>Recep_L_domain</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cell</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein-tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>nucleotide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>purine nucleotide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transferase activity, transferring phosphorus-containing groups</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>adenyl nucleotide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transferase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>catalytic activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane receptor protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>epidermal growth factor receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>physiological process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein amino acid phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>enzyme linked receptor protein signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>macromolecule metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell communication</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>biopolymer metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>biopolymer modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor linked signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein modification</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000858</id>
      <name>Insulin-like growth factor 1 receptor</name>
      <organism>Human</organism>
      <actions/>
      <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
      <known-action>unknown</known-action>
      <polypeptide id="P08069" source="Swiss-Prot">
    <name>Insulin-like growth factor 1 receptor</name>
    <general-function>Involved in transmembrane receptor protein tyrosine kinase activity</general-function>
    <specific-function>This receptor binds insulin-like growth factor 1 (IGF1) with a high affinity and IGF2 with a lower affinity. It has a tyrosine-protein kinase activity, which is necessary for the activation of the IGF1-stimulated downstream signaling cascade</specific-function>
    <gene-name>IGF1R</gene-name>
    <locus>15q26.3</locus>
    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
    <transmembrane-regions>936-959</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>5.54</theoretical-pi>
    <molecular-weight>154795.0</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5465</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IGF1R</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GeneCards</resource>
        <identifier>IGF1R</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X04434</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>804990</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08069</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IGF1R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD221 antigen</synonym>
      <synonym>EC 2.7.10.1</synonym>
      <synonym>IGF-I receptor</synonym>
      <synonym>Insulin-like growth factor 1 receptor precursor</synonym>
      <synonym>Insulin-like growth factor I receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;Insulin-like growth factor 1 receptor precursor
MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH
ILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF
EMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD
LCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS
APDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD
GECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL
LINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF
YVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR
NNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG
QDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE
ILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH
NYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK
VFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES
RVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW
EPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN
YTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR
KRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG
VVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME
LMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN
CMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV
VLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
EIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH
SGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;4104 bp
ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC
GCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC
AACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC
ATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC
ATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC
CCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC
GAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC
ATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC
CTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC
CTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG
TACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG
AAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC
GCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT
GTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC
TTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC
GGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC
TGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC
ATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG
CTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC
ATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC
TTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC
TACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC
ATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC
CGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG
AACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG
TCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC
ATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG
CAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG
GACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC
GTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG
ATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA
TCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC
CTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC
AATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT
GAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC
GCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA
GTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA
GATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA
GACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC
AGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC
ATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC
GTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG
GAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA
TTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG
TCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC
TACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG
TTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG
CCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA
AAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC
TTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC
ATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT
GTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC
ATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC
CATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA
CTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT
AATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA
GACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT
TGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC
TATGAGACAGACTATTACCGGAAAGGAGGCAAAGGGCTGCTGCCCGTGCGCTGGATGTCT
CCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC
GTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA
GTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG
CTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG
GAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC
TACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG
GAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC
TCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC
GACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG
CTGCCCCAGTCTTCGACCTGCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07714</identifier>
        <name>Pkinase_Tyr</name>
      </pfam>
      <pfam>
        <identifier>PF00041</identifier>
        <name>fn3</name>
      </pfam>
      <pfam>
        <identifier>PF00757</identifier>
        <name>Furin-like</name>
      </pfam>
      <pfam>
        <identifier>PF01030</identifier>
        <name>Recep_L_domain</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cell</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein-tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>nucleotide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>purine nucleotide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transferase activity, transferring phosphorus-containing groups</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>adenyl nucleotide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transferase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>catalytic activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane receptor protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>epidermal growth factor receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>physiological process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein amino acid phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>enzyme linked receptor protein signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>macromolecule metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell communication</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>biopolymer metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>biopolymer modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor linked signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein modification</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0002123</id>
      <name>Retinoblastoma-associated protein</name>
      <organism>Human</organism>
      <actions/>
      <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
      <known-action>unknown</known-action>
      <polypeptide id="P06400" source="Swiss-Prot">
    <name>Retinoblastoma-associated protein</name>
    <general-function/>
    <specific-function>Key regulator of entry into cell division that acts as a tumor suppressor. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, SUV420H1 and SUV420H2, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Also acts as a transcription repressor of E2F target genes by recruiting chromatin-modifying enzymes to promoters. Inhibits the intrinsic kinase activity of TAF1. Forms a complex with adenovirus E1A and with SV40 large T antigen. May bind and modulate functionally certain cellular proteins with which T and E1A compete for pocket binding</specific-function>
    <gene-name>RB1</gene-name>
    <locus>13q14.2</locus>
    <cellular-location>Nucleus</cellular-location>
    <transmembrane-regions>None</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.04</theoretical-pi>
    <molecular-weight>106161.0</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9884</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>RB1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GeneCards</resource>
        <identifier>RB1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M15400</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>190959</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P06400</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>RB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>P105-RB</synonym>
      <synonym>PP110</synonym>
      <synonym>RB</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;Retinoblastoma-associated protein
MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTAL
CQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTEL
QKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSS
ISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYK
TAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFM
NSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKS
NLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVK
DIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDN
IFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEG
NLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNH
TAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYL
RLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLK
FKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLS
PIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFG
TSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQK
LAEMTSTRTRMQKQKMNDSMDTSNKEEK</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;2787 bp
ATGCCGCCCAAAACCCCCCGAAAAACGGCCGCCACCGCCGCCGCTGCCGCCGCGGAACCC
CCGGCACCGCCGCCGCCGCCCCCTCCTGAGGAGGACCCAGAGCAGGACAGCGGCCCGGAG
GACCTGCCTCTCGTCAGGCTTGAGTTTGAAGAAACAGAAGAACCTGATTTTACTGCATTA
TGTCAGAAATTAAAGATACCAGATCATGTCAGAGAGAGAGCTTGGTTAACTTGGGAGAAA
GTTTCATCTGTGGATGGAGTATTGGGAGGTTATATTCAAAAGAAAAAGGAACTGTGGGGA
ATCTGTATCTTTATTGCACGAGTTGACCTAGATGAGATGTCGTTCACTTTACTGAGCTAC
AGAAAAACATACGAAATCAGTGTCCATAAATTCTTTAACTTACTAAAAGAAATTGATACC
AGTACCAAAGTTGATAATGCTATGTCAAGACTGTTGAAGAAGTATGATGTATTGTTTGCA
CTCTTCAGCAAATTGGAAAGGACATGTGAACTTATATATTTGACACAACCCAGCAGTTCG
ATATCTACTGAAATAAATTCTGCATTGGTGCTAAAAGTTTCTTGGATCACATTTTTATTA
GCTAAAGGGGAAGTATTACAAATGGAAGATGATCTGGTGATTTCATTTCAGTTAATGCTA
TGTGTCCTTGACTATTTTATTAAACTCTCACCTCCCATGTTGCTCAAAGAACCATATAAA
ACAGCTGTTATACCCATTAATGGTTCACCTCGAACACCCAGGCGAGGTCAGAACAGGAGT
GCACGGATAGCAAAACAACTAGAAAATGATACAAGAATTATTGAAGTTCTCTGTAAAGAA
CATGAATGTAATATAGATGAGGTGAAAAATGTTTATTTCAAAAATTTTATACCTTTTATG
AATTCTCTTGGACTTGTAACATCTAATGGACTTCCAGAGGTTGAAAATCTTTCTAAACGA
TACGAAGAAATTTATCTTAAAAATAAAGATCTAGATCGAAGATTATTTTTGGATCATGAT
AAAACTCTTCAGACTGATTCTATAGACAGTTTTGAAACACAGAGAACACCACGAAAAAGT
AACCTTGATGAAGAGGTGAATATAATTCCTCCACACACTCCAGTTAGGACTGTTATGAAC
ACTATCCAACAATTAATGATGATTTTAAATTCTGCAAGTGATCAACCTTCAGAAAATCTG
ATTTCCTATTTTAACAACTGCACAGTGAATCCAAAAGAAAGTATACTGAAAAGAGTGAAG
GATATAGGATACATCTTTAAAGAGAAATTTGCTAAAGCTGTGGGACAGGGTTGTGTCGAA
ATTGGATCACAGCGATACAAACTTGGAGTTCGCTTGTATTACCGAGTAATGGAATCCATG
CTTAAATCAGAAGAAGAACGATTATCCATTCAAAATTTTAGCAAACTTCTGAATGACAAC
ATTTTTCATATGTCTTTATTGGCGTGCGCTCTTGAGGTTGTAATGGCCACATATAGCAGA
AGTACATCTCAGAATCTTGATTCTGGAACAGATTTGTCTTTCCCATGGATTCTGAATGTG
CTTAATTTAAAAGCCTTTGATTTTTACAAAGTGATCGAAAGTTTTATCAAAGCAGAAGGC
AACTTGACAAGAGAAATGATAAAACATTTAGAACGATGTGAACATCGAATCATGGAATCC
CTTGCATGGCTCTCAGATTCACCTTTATTTGATCTTATTAAACAATCAAAGGACCGAGAA
GGACCAACTGATCACCTTGAATCTGCTTGTCCTCTTAATCTTCCTCTCCAGAATAATCAC
ACTGCAGCAGATATGTATCTTTCTCCTGTAAGATCTCCAAAGAAAAAAGGTTCAACTACG
CGTGTAAATTCTACTGCAAATGCAGAGACACAAGCAACCTCAGCCTTCCAGACCCAGAAG
CCATTGAAATCTACCTCTCTTTCACTGTTTTATAAAAAAGTGTATCGGCTAGCCTATCTC
CGGCTAAATACACTTTGTGAACGCCTTCTGTCTGAGCACCCAGAATTAGAACATATCATC
TGGACCCTTTTCCAGCACACCCTGCAGAATGAGTATGAACTCATGAGAGACAGGCATTTG
GACCAAATTATGATGTGTTCCATGTATGGCATATGCAAAGTGAAGAATATAGACCTTAAA
TTCAAAATCATTGTAACAGCATACAAGGATCTTCCTCATGCTGTTCAGGAGACATTCAAA
CGTGTTTTGATCAAAGAAGAGGAGTATGATTCTATTATAGTATTCTATAACTCGGTCTTC
ATGCAGAGACTGAAAACAAATATTTTGCAGTATGCTTCCACCAGGCCCCCTACCTTGTCA
CCAATACCTCACATTCCTCGAAGCCCTTACAAGTTTCCTAGTTCACCCTTACGGATTCCT
GGAGGGAACATCTATATTTCACCCCTGAAGAGTCCATATAAAATTTCAGAAGGTCTGCCA
ACACCAACAAAAATGACTCCAAGATCAAGAATCTTAGTATCAATTGGTGAATCATTCGGG
ACTTCTGAGAAGTTCCAGAAAATAAATCAGATGGTATGTAACAGCGACCGTGTGCTCAAA
AGAAGTGCTGAAGGAAGCAACCCTCCTAAACCACTGAAAAAACTACGCTTTGATATTGAA
GGATCAGATGAAGCAGATGGAAGTAAACATCTCCCAGGAGAGTCCAAATTTCAGCAGAAA
CTGGCAGAAATGACTTCTACTCGAACACGAATGCAAAAGCAGAAAATGAATGATAGCATG
GATACCTCAAACAAGGAAGAGAAATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01858</identifier>
        <name>RB_A</name>
      </pfam>
      <pfam>
        <identifier>PF01857</identifier>
        <name>RB_B</name>
      </pfam>
      <pfam>
        <identifier>PF08934</identifier>
        <name>Rb_C</name>
      </pfam>
    </pfams>
    <go-classifiers>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0000941</id>
      <name>Cathepsin D</name>
      <organism>Human</organism>
      <actions/>
      <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
      <known-action>unknown</known-action>
      <polypeptide id="P07339" source="Swiss-Prot">
    <name>Cathepsin D</name>
    <general-function>Involved in aspartic-type endopeptidase activity</general-function>
    <specific-function>Acid protease active in intracellular protein breakdown. Involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease</specific-function>
    <gene-name>CTSD</gene-name>
    <locus>11p15.5</locus>
    <cellular-location>Lysosome. Melanosome. Note=Identified by mass spectrometry in melanosome fractions from stage I to s</cellular-location>
    <transmembrane-regions>None</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>6.5</theoretical-pi>
    <molecular-weight>44553.0</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2529</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CTSD</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GeneCards</resource>
        <identifier>CTSD</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M11233</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>181180</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P07339</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CATD_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Cathepsin D precursor</synonym>
      <synonym>EC 3.4.23.5</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;Cathepsin D precursor
MQPSSLLPLALCLLAAPASALVRIPLHKFTSIRRTMSEVGGSVEDLIAKGPVSKYSQAVP
AVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWIH
HKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFG
EATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQNIFSFYLSRDPDAQ
PGGELMLGGTDSKYYKGSLSYLNVTRKAYWQVHLDQVEVASGLTLCKEGCEAIVDTGTSL
MVGPVDEVRELQKAIGAVPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQ
AGKTLCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNRVGFAEAARL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;1239 bp
ATGCAGCCCTCCAGCCTTCTGCCGCTCGCCCTCTGCCTGCTGGCTGCACCCGCCTCCGCG
CTCGTCAGGATCCCGCTGCACAAGTTCACGTCCATCCGCCGGACCATGTCGGAGGTTGGG
GGCTCTGTGGAGGACCTGATTGCCAAAGGCCCCGTCTCAAAGTACTCCCAGGCGGTGCCA
GCCGTGACCGAGGGGCCCATTCCCGAGGTGCTCAAGAACTACATGGACGCCCAGTACTAC
GGGGAGATTGGCATCGGGACGCCCCCCCAGTGCTTCACAGTCGTCTTCGACACGGGCTCC
TCCAACCTGTGGGTCCCCTCCATCCACTGCAAACTGCTGGACATCGCTTGCTGGATCCAC
CACAAGTACAACAGCGACAAGTCCAGCACCTACGTGAAGAATGGTACCTCGTTTGACATC
CACTATGGCTCGGGCAGCCTCTCCGGGTACCTGAGCCAGGACACTGTGTCGGTGCCCTGC
CAGTCAGCGTCGTCAGCCTCTGCCCTGGGCGGTGTCAAAGTGGAGAGGCAGGTCTTTGGG
GAGGCCACCAAGCAGCCAGGCATCACCTTCATCGCAGCCAAGTTCGATGGCATCCTGGGC
ATGGCCTACCCCCGCATCTCCGTCAACAACGTGCTGCCCGTCTTCGACAACCTGATGCAG
CAGAAGCTGGTGGACCAGAACATCTTCTCCTTCTACCTGAGCAGGGACCCAGATGCGCAG
CCTGGGGGTGAGCTGATGCTGGGTGGCACAGACTCCAAGTATTACAAGGGTTCTCTGTCC
TACCTGAATGTCACCCGCAAGGCCTACTGGCAGGTCCACCTGGACCAGGTGGAGGTGGCC
AGCGGGCTGACCCTGTGCAAGGAGGGCTGTGAGGCCATTGTGGACACAGGCACTTCCCTC
ATGGTGGGCCCGGTGGATGAGGTGCGCGAGCTGCAGAAGGCCATCGGGGCCGTGCCGCTG
ATTCAGGGCGAGTACATGATCCCCTGTGAGAAGGTGTCCACCCTGCCCGCGATCACACTG
AAGCTGGGAGGCAAAGGCTACAAGCTGTCCCCAGAGGACTACACGCTCAAGGTGTCGCAG
GCCGGGAAGACCCTCTGCCTGAGCGGCTTCATGGGCATGGACATCCCGCCACCCAGCGGG
CCACTCTGGATCCTGGGCGACGTCTTCATCGGCCGCTACTACACTGTGTTTGACCGTGAC
AACAACAGGGTGGGCTTCGCCGAGGCTGCCCGCCTCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07966</identifier>
        <name>A1_Propeptide</name>
      </pfam>
      <pfam>
        <identifier>PF00026</identifier>
        <name>Asp</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>function</category>
        <description>endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>pepsin A activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>aspartic-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>catalytic activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>hydrolase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>physiological process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>macromolecule metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolism</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="5">
      <id>BE0001183</id>
      <name>Insulin-degrading enzyme</name>
      <organism>Human</organism>
      <actions/>
      <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
      <known-action>unknown</known-action>
      <polypeptide id="P14735" source="Swiss-Prot">
    <name>Insulin-degrading enzyme</name>
    <general-function>Posttranslational modification, protein turnover, chaperones</general-function>
    <specific-function>May play a role in the cellular processing of insulin. May be involved in intercellular peptide signaling</specific-function>
    <gene-name>IDE</gene-name>
    <locus>10q23-q25</locus>
    <cellular-location>Cytoplasm</cellular-location>
    <transmembrane-regions>None</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>6.74</theoretical-pi>
    <molecular-weight>118023.0</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5381</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IDE</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GeneCards</resource>
        <identifier>IDE</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M21188</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>184556</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P14735</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IDE_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>EC 3.4.24.56</synonym>
      <synonym>Insulin protease</synonym>
      <synonym>Insulinase</synonym>
      <synonym>Insulysin</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;Insulin-degrading enzyme
MRYRLAWLLHPALPSTFRSVLGARLPPPERLCGFQKKTYSKMNNPAIKRIGNHITKSPED
KREYRGLELANGIKVLLMSDPTTDKSSAALDVHIGSLSDPPNIAGLSHFCEHMLFLGTKK
YPKENEYSQFLSEHAGSSNAFTSGEHTNYYFDVSHEHLEGALDRFAQFFLCPLFDESCKD
REVNAVDSEHEKNVMNDAWRLFQLEKATGNPKHPFSKFGTGNKYTLETRPNQEGIDVRQE
LLKFHSAYYSSNLMAVCVLGRESLDDLTNLVVKLFSEVENKNVPLPEFPEHPFQEEHLKQ
LYKIVPIKDIRNLYVTFPIPDLQKYYKSNPGHYLGHLIGHEGPGSLLSELKSKGWVNTLV
GGQKEGARGFMFFIINVDLTEEGLLHVEDIILHMFQYIQKLRAEGPQEWVFQECKDLNAV
AFRFKDKERPRGYTSKIAGILHYYPLEEVLTAEYLLEEFRPDLIEMVLDKLRPENVRVAI
VSKSFEGKTDRTEEWYGTQYKQEAIPDEVIKKWQNADLNGKFKLPTKNEFIPTNFEILPL
EKEATPYPALIKDTVMSKLWFKQDDKKKKPKACLNFEFFSPFAYVDPLHCNMAYLYLELL
KDSLNEYAYAAELAGLSYDLQNTIYGMYLSVKGYNDKQPILLKKIIEKMATFEIDEKRFE
IIKEAYMRSLNNFRAEQPHQHAMYYLRLLMTEVAWTKDELKEALDDVTLPRLKAFIPQLL
SRLHIEALLHGNITKQAALGIMQMVEDTLIEHAHTKPLLPSQLVRYREVQLPDRGWFVYQ
QRNEVHNNCGIEIYYQTDMQSTSENMFLELFCQIISEPCFNTLRTKEQLGYIVFSGPRRA
NGIQSLRFIIQSEKPPHYLESRVEAFLITMEKSIEDMTEEAFQKHIQALAIRRLDKPKKL
SAECAKYWGEIISQQYNFDRDNTEVAYLKTLTKEDIIKFYKEMLAVDAPRRHKVSVHVLA
REMDSCPVVGEFPCQNDINLSQAPALPQPEVIQNMTEFKRGLPLFPLVKPHINFMAAKL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;3060 bp
ATGCGGTACCGGCTAGCGTGGCTTCTGCACCCCGCACTGCCCAGCACCTTCCGCTCAGTC
CTCGGCGCCCGCCTGCCGCCTCCGGAGCGCCTGTGTGGTTTCCAAAAAAAGACTTACAGC
AAAATGAATAATCCAGCCATCAAGAGAATAGGAAATCACATTACCAAGTCTCCTGAAGAC
AAGCGAGAATATCGAGGGCTAGAGCTGGCCAATGGTATCAAAGTACTTCTTATGAGTGAT
CCCACCACGGATAAGTCATCAGCAGCACTTGATGTGCACATAGGTTCATTGTCGGATCCT
CCAAATATTGCTGGCTTAAGTCATTTTTGTGAACATATGCTTTTTTTGGGAACAAAGAAA
TACCCTAAAGAAAATGAATACAGCCAGTTTCTCAGTGAGCATGCAGGAAGTTCAAATGCC
TTTACTAGTGGAGAGCATACCAATTACTATTTTGATGTTTCTCATGAACACCTAGAAGGT
GCCCTAGACAGGTTTGCACAGTTTTTTCTGTGCCCCTTGTTCGATGAAAGTTGCAAAGAC
AGAGAGGTGAATGCAGTTGATTCAGAACATGAGAAGAATGTGATGAATGATGCCTGGAGA
CTCTTTCAATTGGAAAAAGCTACAGGGAATCCTAAACACCCCTTCAGTAAATTTGGGACA
GGTAACAAATATACTCTGGAGACTAGACCAAACCAAGAAGGCATTGATGTAAGACAAGAG
CTACTGAAATTCCATTCTGCTTACTATTCATCCAACTTAATGGCTGTTTGTGTTTTAGGT
CGAGAATCTTTAGATGACTTGACTAATCTGGTGGTAAAGTTATTTTCTGAAGTAGAGAAC
AAAAATGTTCCATTGCCAGAATTTCCTGAACACCCTTTCCAAGAAGAACATCTTAAACAA
CTTTACAAAATAGTACCCATTAAAGATATTAGGAATCTCTATGTGACATTTCCCATACCT
GACCTTCAGAAATACTACAAATCAAATCCTGGTCATTATCTTGGTCATCTCATTGGGCAT
GAAGGTCCTGGAAGTCTGTTATCAGAACTTAAGTCAAAGGGCTGGGTTAATACTCTTGTT
GGTGGGCAGAAGGAAGGAGCCCGAGGTTTTATGTTTTTTATCATTAATGTGGACTTGACC
GAGGAAGGATTATTACATGTTGAAGATATAATTTTGCACATGTTTCAATACATTCAGAAG
TTACGTGCAGAAGGACCTCAAGAATGGGTTTTCCAAGAGTGCAAGGACTTGAATGCTGTT
GCTTTTAGGTTTAAAGACAAAGAGAGGCCACGGGGCTATACATCTAAGATTGCAGGAATA
TTGCATTATTATCCCCTAGAAGAGGTGCTCACAGCGGAATATTTACTGGAAGAATTTAGA
CCTGACTTAATAGAGATGGTTCTCGATAAACTCAGACCAGAAAATGTCCGGGTTGCCATA
GTTTCTAAATCTTTTGAAGGAAAAACTGATCGCACAGAAGAGTGGTATGGAACCCAGTAC
AAACAAGAAGCTATACCGGATGAAGTCATCAAGAAATGGCAAAATGCTGACCTGAATGGG
AAATTTAAACTTCCTACAAAGAATGAATTTATTCCTACGAATTTTGAGATTTTACCGTTA
GAAAAAGAGGCGACACCATACCCTGCTCTTATTAAGGATACAGTCATGAGCAAACTTTGG
TTCAAACAAGATGATAAGAAAAAAAAGCCGAAGGCTTGTCTCAACTTTGAATTTTTCAGC
CCATTTGCTTATGTGGACCCCTTGCACTGTAACATGGCCTATTTGTACCTTGAGCTCCTC
AAAGACTCACTCAACGAGTATGCATATGCAGCAGAGCTAGCAGGCTTGAGCTATGATCTC
CAAAATACCATCTATGGGATGTATCTTTCAGTGAAAGGTTACAATGACAAGCAGCCAATT
TTACTAAAGAAGATTATTGAGAAAATGGCTACCTTTGAGATTGATGAAAAAAGATTTGAA
ATTATCAAAGAAGCATATATGCGATCTCTTAACAATTTCCGGGCTGAACAGCCTCACCAG
CATGCCATGTACTACCTCCGCTTGCTGATGACTGAAGTGGCCTGGACTAAAGATGAGTTA
AAAGAAGCTCTGGATGATGTAACCCTTCCTCGCCTTAAGGCCTTCATACCTCAGCTCCTG
TCACGGCTGCACATTGAAGCCCTTCTCCATGGAAACATAACAAAGCAGGCTGCATTAGGA
ATTATGCAGATGGTTGAAGACACCCTCATTGAACATGCTCATACCAAACCTCTCCTTCCA
AGTCAGCTGGTTCGGTATAGAGAAGTTCAGCTCCCTGACAGAGGATGGTTTGTTTATCAG
CAGAGAAATGAAGTTCACAATAACTGTGGCATCGAGATATACTACCAAACAGACATGCAA
AGCACCTCAGAGAATATGTTTCTGGAGCTCTTCTGTCAGATTATCTCGGAACCTTGCTTC
AACACCCTGCGCACCAAGGAGCAGTTGGGCTATATCGTCTTCAGCGGGCCACGTCGAGCT
AATGGCATACAGAGCTTGAGATTCATCATCCAGTCAGAAAAGCCACCTCACTACCTAGAA
AGCAGAGTGGAAGCTTTCTTAATTACCATGGAAAAGTCCATAGAGGACATGACAGAAGAG
GCCTTCCAAAAACACATTCAGGCATTAGCAATTCGTCGACTAGACAAACCAAAGAAGCTA
TCTGCTGAGTGTGCTAAATACTGGGGAGAAATCATCTCCCAGCAATATAATTTTGACAGA
GATAACACTGAGGTTGCATATTTAAAGACACTTACCAAGGAAGATATCATCAAATTCTAC
AAGGAAATGTTGGCAGTAGATGCTCCAAGGAGACATAAGGTATCCGTCCATGTTCTTGCC
AGGGAAATGGATTCTTGTCCTGTTGTTGGAGAGTTCCCATGTCAAAATGACATAAATTTG
TCACAAGCACCAGCCTTGCCACAACCTGAAGTGATTCAGAACATGACCGAATTCAAGCGT
GGTCTGCCACTGTTTCCCCTTGTGAAACCACATATTAACTTCATGGCTGCAAAACTCTGA
</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00675</identifier>
        <name>Peptidase_M16</name>
      </pfam>
      <pfam>
        <identifier>PF05193</identifier>
        <name>Peptidase_M16_C</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>function</category>
        <description>endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metalloendopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>catalytic activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>hydrolase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>physiological process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>macromolecule metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolism</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="6">
      <id>BE0002124</id>
      <name>Neuroendocrine convertase 2</name>
      <organism>Human</organism>
      <actions/>
      <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
      <known-action>unknown</known-action>
      <polypeptide id="P16519" source="Swiss-Prot">
    <name>Neuroendocrine convertase 2</name>
    <general-function>Posttranslational modification, protein turnover, chaperones</general-function>
    <specific-function>Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues</specific-function>
    <gene-name>PCSK2</gene-name>
    <locus>20p11.2</locus>
    <cellular-location>Cytoplasmic vesicle</cellular-location>
    <transmembrane-regions>None</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>6.47</theoretical-pi>
    <molecular-weight>70566.0</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8744</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PCSK2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GeneCards</resource>
        <identifier>PCSK2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J05252</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>189652</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P16519</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>NEC2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>EC 3.4.21.94</synonym>
      <synonym>KEX2-like endoprotease 2</synonym>
      <synonym>NEC 2</synonym>
      <synonym>Neuroendocrine convertase 2 precursor</synonym>
      <synonym>PC2</synonym>
      <synonym>Prohormone convertase 2</synonym>
      <synonym>Proprotein convertase 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;Neuroendocrine convertase 2
MKGGCVSQWKAAAGFLFCVMVFASAERPVFTNHFLVELHKGGEDKARQVAAEHGFGVRKL
PFAEGLYHFYHNGLAKAKRRRSLHHKQQLERDPRVKMALQQEGFDRKKRGYRDINEIDIN
MNDPLFTKQWYLINTGQADGTPGLDLNVAEAWELGYTGKGVTIGIMDDGIDYLHPDLASN
YNAEASYDFSSNDPYPYPRYTDDWFNSHGTRCAGEVSAAANNNICGVGVAYNSKVAGIRM
LDQPFMTDIIEASSISHMPQLIDIYSASWGPTDNGKTVDGPRELTLQAMADGVNKGRGGK
GSIYVWASGDGGSYDDCNCDGYASSMWTISINSAINDGRTALYDESCSSTLASTFSNGRK
RNPEAGVATTDLYGNCTLRHSGTSAAAPEAAGVFALALEANLGLTWRDMQHLTVLTSKRN
QLHDEVHQWRRNGVGLEFNHLFGYGVLDAGAMVKMAKDWKTVPERFHCVGGSVQDPEKIP
STGKLVLTLTTDACEGKENFVRYLEHVQAVITVNATRRGDLNINMTSPMGTKSILLSRRP
RDDDSKVGFDKWPFMTTHTWGEDARGTWTLELGFVGSAPQKGVLKEWTLMLHGTQSAPYI
DQVVRDYQSKLAMSKKEELEEELDEAVERSLKSILNKN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;1917 bp
ATGAAGGGTGGTTGTGTCTCCCAGTGGAAGGCGGCCGCCGGGTTCCTCTTCTGTGTCATG
GTTTTTGCATCTGCTGAGCGACCGGTCTTCACGAATCATTTTCTTGTGGAGTTGCATAAA
GGGGGAGAGGACAAAGCTCGCCAAGTTGCAGCAGAACACGGCTTTGGAGTCCGAAAGCTT
CCCTTTGCTGAAGGTCTGTACCACTTTTATCACAATGGCCTTGCAAAGGCCAAGAGAAGA
CGCAGCCTACACCACAAGCAGCAGCTGGAGAGAGACCCCAGGGTAAAGATGGCTTTGCAG
CAGGAAGGATTTGACCGAAAAAAGCGAGGTTACAGAGACATCAATGAGATCGACATCAAC
ATGAACGATCCTCTTTTTACAAAGCAGTGGTATCTGATCAATACTGGGCAAGCTGATGGC
ACTCCTGGCCTTGATTTGAATGTGGCTGAAGCCTGGGAGCTGGGATACACAGGGAAAGGT
GTTACCATTGGAATTATGGATGATGGGATTGACTATCTCCACCCGGACCTGGCCTCCAAC
TATAATGCCGAAGCAAGTTACGACTTCAGCAGCAACGACCCCTATCCTTACCCTCGGTAC
ACAGATGACTGGTTTAACAGCCACGGGACCCGATGTGCAGGAGAAGTTTCTGCTGCCGCC
AACAACAATATCTGTGGAGTTGGAGTAGCATACAACTCCAAGGTTGCAGGCATCCGGATG
CTGGACCAGCCATTCATGACAGACATCATCGAGGCCTCCTCCATCAGTCATATGCCACAG
CTGATTGACATCTACAGCGCCAGCTGGGGCCCCACAGACAACGGCAAGACAGTGGATGGG
CCCCGGGACGTCACGCTGCAGGCCATGGCCGATGGCGTGAACAAGGGCCGCGGCGGCAAA
GGCAGCATCTACGTGTGGGCCTCCGGGGACGGCGGCAGCTATGACGACTGCAACTGCGAC
GGCTACGCCTCCAGCATGTGGACCATCTCCATCAACTCAGCCATCAACGACGGCAGGACT
GCCCTGTACGACGAGAGCTGCTCTTCCACCTTGGCTTCCACCTTCAGCAACGGGAGGAAA
AGGAACCCCGAGGCCGGTGTGGCAACCACAGATTTGTACGGCAACTGCACTCTGAGGCAT
TCTGGGACATCTGCAGCTGCCCCCGAGGCAGCTGGTGTGTTTGCACTGGCTCTGGAGGCT
AACCTGGGTCTGACCTGGCGGGACATGCAGCATCTGACTGTGCTCACCTCCAAACGGAAC
CAGCTTCACGACGAGGTCCATCAGTGGCGGCGCAATGGGGTCGGCCTGGAATTTAATCAC
CTCTTTGGCTACGGGGTCCTTGATGCAGGTGCCATGGTGAAAATGGCTAAAGACTGGAAA
ACCGTGCCTGAGAGATTCCACTGTGTGGGAGGCTCCGTGCAGGACCCTGAGAAAATACCA
TCCACTGGCAAGTTGGTGCTGACACTCACAACCGACGCCTGTGAGGGGAAGGAAAATTTT
GTCCGCTACCTGGAGCATGTCCAGGCTGTCATCACGGTCAACGCAACCAGAAGAGGAGAC
CTGAACATCAACATGACTTCCCCTATGGGCACCAAGTCCATTTTGCTGAGCCGGCGTCCA
AGGGATGACGACTCCAAGGTGGGCTTTGACAAGTGGCCTTTCATGACCACTCACACGTGG
GGGGAAGACGCCCGAGGCACCTGGACCCTGGAGCTGGGATTTGTCGGCAGCGCCCCGCAG
AAGGGGGTGCTGAAGGAGTGGACCCTGATGCTGCATGGCACTCAGAGTGCCCCGTACATC
GACCAGGTGGTGCGGGATTACCAGTCCAAGTTGGCCATGTCCAAGAAAGAGGAGCTGGAG
GAAGAGCTGGACGAAGCCGTGGAGAGAAGCCTGAAAAGCATCCTTAACAAGAACTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00082</identifier>
        <name>Peptidase_S8</name>
      </pfam>
      <pfam>
        <identifier>PF01483</identifier>
        <name>P_proprotein</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>function</category>
        <description>endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>subtilase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>catalytic activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>hydrolase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>physiological process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>macromolecule metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolism</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="7">
      <id>BE0001123</id>
      <name>Carboxypeptidase E</name>
      <organism>Human</organism>
      <actions/>
      <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
      <known-action>unknown</known-action>
      <polypeptide id="P16870" source="Swiss-Prot">
    <name>Carboxypeptidase E</name>
    <general-function>Amino acid transport and metabolism</general-function>
    <specific-function>Removes residual C-terminal Arg or Lys remaining after initial endoprotease cleavage during prohormone processing. Processes proinsulin</specific-function>
    <gene-name>CPE</gene-name>
    <locus>4q32.3</locus>
    <cellular-location>Secreted protein. Note=Secretory granules of pancreatic islets, adrenal gland, pituitary and brain</cellular-location>
    <transmembrane-regions>None</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>4.78</theoretical-pi>
    <molecular-weight>53151.0</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2303</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CPE</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GeneCards</resource>
        <identifier>CPE</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X51405</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>29667</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P16870</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CBPE_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Carboxypeptidase E precursor</synonym>
      <synonym>Carboxypeptidase H</synonym>
      <synonym>CPE</synonym>
      <synonym>CPH</synonym>
      <synonym>EC 3.4.17.10</synonym>
      <synonym>Enkephalin convertase</synonym>
      <synonym>Prohormone-processing carboxypeptidase</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;Carboxypeptidase E precursor
MAGRGGSALLALCGALAACGWLLGAEAQEPGAPAAGMRRRRRLQQEDGISFEYHRYPELR
EALVSVWLQCTAISRIYTVGRSFEGRELLVIELSDNPGVHEPGEPEFKYIGNMHGNEAVG
RELLIFLAQYLCNEYQKGNETIVNLIHSTRIHIMPSLNPDGFEKAASQPGELKDWFVGRS
NAQGIDLNRNFPDLDRIVYVNEKEGGPNNHLLKNMKKIVDQNTKLAPETKAVIHWIMDIP
FVLSANLHGGDLVANYPYDETRSGSAHEYSSSPDDAIFQSLARAYSSFNPAMSDPNRPPC
RKNDDDSSFVDGTTNGGAWYSVPGGMQDFNYLSSNCFEITVELSCEKFPPEETLKTYWED
NKNSLISYLEQIHRGVKGFVRDLQGNPIANATISVEGIDHDVTSAKDGDYWRLLIPGNYK
LTASAPGYLAITKKVAVPYSPAAGVDFELESFSERKEEEKEELMEWWKMMSETLNF</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;1431 bp
ATGGCCGGGCGAGGGGGCAGCGCGCTGCTGGCTCTGTGCGGGGCACTGGCTGCCTGCGGG
TGGCTCCTGGGCGCCGAAGCCCAGGAGCCCGGGGCGCCCGCGGCGGGCATGAGGCGGCGC
CGGCGGCTGCAGCAAGAGGACGGCATCTCCTTCGAGTACCACCGCTACCCCGAGCTGCGC
GAGGCGCTCGTGTCCGTGTGGCTGCAGTGCACCGCCATCAGCAGGATTTACACGGTGGGG
CGCAGCTTCGAGGGCCGGGAGCTCCTGGTCATCGAGCTGTCCGACAACCCTGGCGTCCAT
GAGCCTGGTGAGCCTGAATTTAAATACATTGGGAATATGCATGGGAATGAGGCTGTTGGA
CGAGAACTGCTCATTTTCTTGGCCCAGTACCTATGCAACGAATACCAGAAGGGGAACGAG
ACAATTGTCAACCTGATCCACAGTACCCGCATTCACATCATGCCTTCCCTGAACCCAGAT
GGCTTTGAGAAGGCAGCGTCTCAGCCTGGTGAACTCAAGGACTGGTTTGTGGGTCGAAGC
AATGCCCAGGGAATAGATCTGAACCGGAACTTTCCAGACCTGGATAGGATAGTGTACGTG
AATGAGAAAGAAGGTGGTCCAAATAATCATCTGTTGAAAAATATGAAGAAAATTGTGGAT
CAAAACACAAAGCTTGCTCCTGAGACCAAGGCTGTCATTCATTGGATTATGGATATTCCT
TTTGTGCTTTCTGCCAATCTCCATGGAGGAGACCTTGTGGCCAATTATCCATATGATGAG
ACGCGGAGTGGTAGTGCTCACGAATACAGCTCCTCCCCAGATGACGCCATTTTCCAAAGC
TTGGCCCGGGCATACTCTTCTTTCAACCCGGCCATGTCTGACCCCAATCGGCCACCATGT
CGCAAGAATGATGATGACAGCAGCTTTGTAGATGGAACCACCAACGGTGGTGCTTGGTAC
AGCGTACCTGGAGGGATGCAAGACTTCAATTACCTTAGCAGCAACTGTTTTGAGATCACC
GTGGAGCTTAGCTGTGAGAAGTTCCCACCTGAAGAGACTCTGAAGACCTACTGGGAGGAT
AACAAAAACTCCCTCATTAGCTACCTTGAGCAGATACACCGAGGAGTTAAAGGATTTGTC
CGAGACCTTCAAGGTAACCCAATTGCGAATGCCACCATCTCCGTGGAAGGAATAGACCAC
GATGTTACATCCGCAAAGGATGGTGATTACTGGAGATTGCTTATACCTGGAAACTATAAA
CTTACAGCCTCAGCTCCAGGCTATCTGGCAATAACAAAGAAAGTGGCAGTTCCTTACAGC
CCTGCTGCTGGGGTTGATTTTGAACTGGAGTCATTTTCTGAAAGGAAAGAAGAGGAGAAG
GAAGAATTGATGGAATGGTGGAAAATGATGTCAGAAACTTTAAATTTTTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00246</identifier>
        <name>Peptidase_M14</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>function</category>
        <description>exopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>carboxypeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metallocarboxypeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>catalytic activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>carboxypeptidase A activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>hydrolase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>physiological process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>macromolecule metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolism</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="8">
      <id>BE0002125</id>
      <name>Neuroendocrine convertase 1</name>
      <organism>Human</organism>
      <actions/>
      <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
      <known-action>unknown</known-action>
      <polypeptide id="P29120" source="Swiss-Prot">
    <name>Neuroendocrine convertase 1</name>
    <general-function>Posttranslational modification, protein turnover, chaperones</general-function>
    <specific-function>Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Substrates include POMC, renin, enkephalin, dynorphin, somatostatin and insulin</specific-function>
    <gene-name>PCSK1</gene-name>
    <locus>5q15-q21</locus>
    <cellular-location>Cytoplasmic vesicle</cellular-location>
    <transmembrane-regions>None</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>5.84</theoretical-pi>
    <molecular-weight>84152.0</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8743</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PCSK1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GeneCards</resource>
        <identifier>PCSK1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X64810</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>35318</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P29120</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>NEC1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>EC 3.4.21.93</synonym>
      <synonym>NEC 1</synonym>
      <synonym>Neuroendocrine convertase 1 precursor</synonym>
      <synonym>PC1</synonym>
      <synonym>Prohormone convertase 1</synonym>
      <synonym>Proprotein convertase 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;Neuroendocrine convertase 1
MERRAWSLQCTAFVLFCAWCALNSAKAKRQFVNEWAAEIPGGPEAASAIAEELGYDLLGQ
IGSLENHYLFKHKNHPRRSRRSAFHITKRLSDDDRVIWAEQQYEKERSKRSALRDSALNL
FNDPMWNQQWYLQDTRMTAALPKLDLHVIPVWQKGITGKGVVITVLDDGLEWNHTDIYAN
YDPEASYDFNDNDHDPFPRYDPTNENKHGTRCAGEIAMQANNHKCGVGVAYNSKVGGIRM
LDGIVTDAIEASSIGFNPGHVDIYSASWGPNDDGKTVEGPGRLAQKAFEYGVKQGRQGKG
SIFVWASGNGGRQGDNCDCDGYTDSIYTISISSASQQGLSPWYAEKCSSTLATSYSSGDY
TDQRITSADLHNDCTETHTGTSASAPLAAGIFALALEANPNLTWRDMQHLVVWTSEYDPL
ANNPGWKKNGAGLMVNSRFGFGLLNAKALVDLADPRTWRSVPEKKECVVKDNDFEPRALK
ANGEVIIEIPTRACEGQENAIKSLEHVQFEATIEYSRRGDLHVTLTSAAGTSTVLLAERE
RDTSPNGFKNWDFMSVHTWGENPIGTWTLRITDMSGRIQNEGRIVNWKLILHGTSSQPEH
MKQPRVYTSYNTVQNDRRGVEKMVDPGEEQPTQENPKENTLVSKSPSSSSVGGRRDELEE
GAPSQAMLRLLQSAFSKNSPPKQSPKKSPSAKLNIPYENFYEALEKLNKPSQLKDSEDSL
YNDYVDVFYNTKPYKHRDDRLLQALVDILNEEN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;2262 bp
ATGGAGCGAAGAGCCTGGAGTCTGCAGTGCACTGCTTTCGTCCTCTTTTGCGCTTGGTGT
GCACTGAACAGTGCAAAAGCGAAAAGGCAATTTGTCAATGAATGGGCAGCGGAGATCCCC
GGGGGCCCGGAAGCAGCCTCGGCCATCGCCGAGGAGCTGGGCTATGACCTTTTGGGTCAG
ATTGGTTCACTTGAAAATCACTACTTATTCAAACATAAAAACCACCCCAGAAGGTCTCGA
AGGAGTGCCTTTCATATCACTAAGAGATTATCTGATGATGATCGTGTGATATGGGCTGAA
CAACAGTATGAAAAAGAAAGAAGTAAACGTTCAGCTCTAAGGGACTCAGCACTAAATCTC
TTCAATGATCCCATGTGGAATCAGCAATGGTACTTGCAAGATACCAGGATGACGGCAGCC
CTGCCCAAGCTGGACCTTCATGTGATACCTGTTTGGCAAAAAGGCATTACGGGCAAAGGA
GTTGTTATCACCGTACTGGATGATGGTTTGGAGTGGAATCACACGGACATTTATGCCAAC
TATGATCCAGAGGCTAGCTATGATTTTAATGATAATGACCATGATCCATTTCCCCGATAT
GATCCCACAAACGAGAACAAACACGGGACCAGATGTGCAGGAGAAATTGCCATGCAAGCA
AATAATCACAAATGCGGGGTTGGAGTTGCATACAATTCCAAAGTTGGAGGCATAAGAATG
CTGGATGGCATTGTGACGGATGCTATTGAGGCCAGTTCAATTGGATTCAATCCTGGACAC
GTGGATATTTACAGTGCAAGCTGGGGCCCTAATGATGATGGGAAAACTGTGGAGGGGCCT
GGCCGGCTAGCCCAGAAGGCTTTTGAATATGGTGTCAAACAGGGGAGACAGGGGAAGGGG
TCCATCTTCGTCTGGGCTTCGGGAAACGGGGGGCGTCAGGGAGATAATTGTGACTGTGAT
GGCTACACAGACAGCATCTACACCATCTCCATCAGCAGTGCCTCCCAGCAAGGCCTATCC
CCCTGGTACGCTGAGAAGTGCTCCTCCACACTGGCCACCTCTTACAGCGGCGGAGATTAC
ACCGACCAGAGAATCACGAGCGCTGACCTGCACAATGACTGCACGGAGACGCACACAGGC
ACCTCGGCCTCTGCACCTCTGGCTGCTGGCATCTTCGCTCTGGCCCTGGAAGCAAACCCA
AATCTCACCTGGCGAGATATGCAGCACCTGGTTGTCTGGACCTCTGAGTATGACCCGCTG
GCCAATAACCCTGGATGGAAAAAGAATGGAGCAGGCTTGATGGTGAATAGTCGATTTGGA
TTTGGCTTGCTAAATGCCAAAGCTCTGGTGGATTTAGCTGACCCCAGGACCTGGAGGAGC
GTGCCTGAGAAGAAAGAGTGTGTTGTAAAGGACAATGACTTTGAGCCCAGAGCCCTGAAA
GCTAATGGAGAAGTTATCATTGAAATTCCAACAAGAGCTTGTGAAGGACAAGAAAATGCT
ATCAAGTCCCTGGAGCATGTACAATTTGAAGCAACAATTGAATATTCCCGAAGAGGAGAC
CTTCATGTCACACTTACTTCTGCTGCTGGAACTAGCACTGTGCTCTTGGCTGAAAGAGAA
CGGGATACATCTCCTAATGGCTTTAAGAACTGGGACTTCATGTCTGTTCACACATGGGGA
GAGAACCCTATAGGTACTTGGACTTTGAGAATTACAGACATGTCTGGAAGAATTCAAAAT
GAAGGAAGAATTGTGAACTGGAAGCTGATTTTGCACGGGACCTCTTCTCAGCCAGAGCAT
ATGAAGCAGCCTCGTGTGTACACGTCCTACAACACTGTTCAGAATGACAGAAGAGGGGTG
GAGAAGATGGTGGATCCAGGGGAGGAGCAGCCCACACAAGAGAACCCTAAGGAGAACACC
CTGGTGTCCAAAAGCCCCAGCAGCAGCAGCGTAGGGGGCCGGAGGGATGAGTTGGAGGAG
GGAGCCCCTTCCCAGGCCATGCTGCGACTCCTGCAAAGTGCTTTCAGTAAAAACTCACCG
CCAAAGCAATCACCAAAGAAGTCCCCAAGTGCAAAGCTCAACATCCCTTATGAAAACTTC
TACGAAGCCCTGGAAAAGCTGAACAAACCTTCCCAGCTTAAAGACTCTGAAGACAGTCTG
TATAATGACTATGTTGATGTTTTTTATAACACTAAACCTTACAAGCACAGAGACGACCGG
CTGCTTCAAGCTCTGGTGGACATTCTGAATGAGGAAAATTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00082</identifier>
        <name>Peptidase_S8</name>
      </pfam>
      <pfam>
        <identifier>PF01483</identifier>
        <name>P_proprotein</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>function</category>
        <description>endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>subtilase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>catalytic activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>hydrolase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>physiological process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>macromolecule metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolism</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="9">
      <id>BE0001147</id>
      <name>Protein NOV homolog</name>
      <organism>Human</organism>
      <actions/>
      <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
      <known-action>unknown</known-action>
      <polypeptide id="P48745" source="Swiss-Prot">
    <name>Protein NOV homolog</name>
    <general-function>Involved in insulin-like growth factor binding</general-function>
    <specific-function>Immediate-early protein likely to play a role in cell growth regulation</specific-function>
    <gene-name>NOV</gene-name>
    <locus>8q24.1</locus>
    <cellular-location>Secreted protein</cellular-location>
    <transmembrane-regions>None</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>7.74</theoretical-pi>
    <molecular-weight>39162.0</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:7885</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>NOV</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GeneCards</resource>
        <identifier>NOV</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X78351</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>825696</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P48745</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>NOV_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Nephroblastoma overexpressed gene protein homolog</synonym>
      <synonym>NovH</synonym>
      <synonym>Protein NOV homolog precursor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;Protein NOV homolog precursor
MQSVQSTSFCLRKQCLCLTFLLLHLLGQVAATQRCPPQCPGRCPATPPTCAPGVRAVLDG
CSCCLVCARQRGESCSDLEPCDESSGLYCDRSADPSNQTGICTAVEGDNCVFDGVIYRSG
EKFQPSCKFQCTCRDGQIGCVPRCQLDVLLPEPNCPAPRKVEVPGECCEKWICGPDEEDS
LGGLTLAAYRPEATLGVEVSDSSVNCIEQTTEWTACSKSCGMGFSTRVTNRNRQCEMLKQ
TRLCMVRPCEQEPEQPTDKKGKKCLRTKKSLKAIHLQFKNCTSLHTYKPRFCGVCSDGRC
CTPHNTKTIQAEFQCSPGQIVKKPVMVIGTCTCHTNCPKNNEAFLQELELKTTRGKM</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;1074 bp
ATGCAGAGTGTGCAGAGCACGAGCTTTTGTCTCCGAAAGCAGTGCCTTTGCCTGACCTTC
CTGCTTCTCCATCTCCTGGGACAGGTCGCTGCGACTCAGCGCTGCCCTCCCCAGTGCCCG
GGCCGGTGCCCTGCGACGCCGCCGACCTGCGCCCCCGGGGTGCGCGCGGTGCTGGACGGC
TGCTCATGCTGTCTGGTGTGTGCCCGCCAGCGTGGCGAGAGCTGCTCAGATCTGGAGCCA
TGCGACGAGAGCAGTGGCCTCTACTGTGATCGCAGCGCGGACCCCAGCAACCAGACTGGC
ATCTGCACGGCGGTAGAGGGAGATAACTGTGTGTTCGATGGGGTCATCTACCGCAGTGGA
GAGAAATTTCAGCCAAGCTGCAAATTCCAGTGCACCTGCAGAGATGGGCAGATTGGCTGT
GTGCCCCGCTGTCAGCTGGATGTGCTACTGCCTGAGCCTAACTGCCCAGCTCCAAGAAAA
GTTGAGGTGCCTGGAGAGTGCTGTGAAAAGTGGATCTGTGGCCCAGATGAGGAGGATTCA
CTGGGAGGCCTTACCCTTGCAGCTTACAGGCCAGAAGCCACCCTAGGAGTAGAAGTCTCT
GACTCAAGTGTCAACTGCATTGAACAGACCACAGAGTGGACAGCATGCTCCAAGAGCTGT
GGTATGGGGTTCTCCACCCGGGTCACCAATAGGAACCGTCAATGTGAGATGCTGAAACAG
ACTCGGCTCTGCATGGTGCGGCCCTGTGAACAAGAGCCAGAGCAGCCAACAGATAAGAAA
GGAAAAAAGTGTCTCCGCACCAAGAAGTCACTCAAAGCCATCCACCTGCAGTTCAAGAAC
TGCACCAGCCTGCACACCTACAAGCCCAGGTTCTGTGGGGTCTGCAGTGATGGCCGCTGC
TGCACTCCCCACAATACCAAAACCATCCAGGCAGAGTTTCAGTGCTCCCCAGGGCAAATA
GTCAAGAAGCCAGTGATGGTCATTGGGACCTGCACCTGTCACACCAACTGTCCTAAGAAC
AATGAGGCCTTCCTCCAGGAGCTGGAGCTGAAGACTACCAGAGGGAAAATGTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00093</identifier>
        <name>VWC</name>
      </pfam>
      <pfam>
        <identifier>PF00219</identifier>
        <name>IGFBP</name>
      </pfam>
      <pfam>
        <identifier>PF00007</identifier>
        <name>Cys_knot</name>
      </pfam>
      <pfam>
        <identifier>PF00090</identifier>
        <name>TSP_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>growth factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin-like growth factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of biological process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell growth</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="10">
      <id>BE0000942</id>
      <name>Low-density lipoprotein receptor-related protein 2</name>
      <organism>Human</organism>
      <actions/>
      <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
      <known-action>unknown</known-action>
      <polypeptide id="P98164" source="Swiss-Prot">
    <name>Low-density lipoprotein receptor-related protein 2</name>
    <general-function>Involved in calcium ion binding</general-function>
    <specific-function>May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release</specific-function>
    <gene-name>LRP2</gene-name>
    <locus>2q24-q31</locus>
    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
    <transmembrane-regions>4424-4446</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>4.68</theoretical-pi>
    <molecular-weight>521933.0</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6694</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>LRP2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GeneCards</resource>
        <identifier>LRP2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U33837</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>1809240</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P98164</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>LRP2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Glycoprotein 330</synonym>
      <synonym>gp330</synonym>
      <synonym>Low-density lipoprotein receptor-related protein 2 precursor</synonym>
      <synonym>Megalin</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;Low-density lipoprotein receptor-related protein 2 precursor
MDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEI
GCAVVTCQQGYFKCQSEGQCIPSSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQC
IPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCT
EICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWV
CDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENN
TSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQ
KCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVES
QNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNK
IYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLER
AFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSL
IPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYAT
NPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIR
GIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAA
NRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYL
FFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFD
GLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHL
KSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNE
PPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECI
PAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDE
KNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKC
IGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGS
DEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCL
GHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFL
LANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLV
ASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDR
RVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALD
PRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLD
YMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVM
YNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNC
LRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGE
IHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTL
IANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEH
LECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQY
EVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGL
FSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHV
DVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLY
FTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFL
DCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTP
YGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAE
VNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRS
LHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTV
IASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGY
LYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTL
TGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGI
NTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERC
GASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRC
DYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDR
TCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQH
WYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKR
HQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTC
GYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDG
SDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSIS
GCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAP
GYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKR
LYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLN
GGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVII
STKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTI
YWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLC
LIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSD
GSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQ
CANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDC
GDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCH
PVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDH
YNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGA
YCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSH
EVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDEL
GCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQH
CRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQD
EEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKY
VMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMF
WTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYD
GTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRI
FHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPP
CRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGAL
AIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAI
DRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSE
IVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLP
AKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;13968 bp
ATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTA
GCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGC
ATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATT
GGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGC
ATCCCCAGCTCCTGGGTGTGTGACCAAGATCAAGACTGTGATGATGGCTCAGATGAACGT
CAAGATTGCTCACAAAGTACATGCTCAAGTCATCAGATAACATGCTCCAATGGTCAGTGT
ATCCCAAGTGAATACAGGTGCGACCACGTCAGAGACTGCCCCGATGGAGCTGATGAGAAT
GACTGCCAGTACCCAACATGTGAGCAGCTTACTTGTGACAATGGGGCCTGCTATAACACC
AGTCAGAAGTGTGATTGGAAAGTTGATTGCAGGGACTCCTCAGATGAAATCAACTGCACT
GAGATATGCTTGCACAATGAGTTTTCATGTGGCAATGGAGAGTGTATCCCTCGTGCTTAT
GTCTGTGACCATGACAATGATTGCCAAGACGGCAGTGATGAACATGCTTGCAACTATCCG
ACCTGCGGTGGTTACCAGTTCACTTGCCCCAGTGGCCGATGCATTTATCAAAACTGGGTT
TGTGATGGAGAAGATGACTGTAAAGATAATGGAGATGAAGATGGATGTGAAAGCGGTCCT
CATGATGTTCATAAATGTTCCCCAAGAGAATGGTCTTGCCCAGAGTCGGGACGATGCATC
TCCATTTATAAAGTTTGTGATGGGATTTTAGATTGCCCAGGAAGAGAAGATGAAAACAAC
ACTAGTACCGGAAAATACTGTAGTATGACTCTGTGCTCTGCCTTGAACTGCCAGTACCAG
TGCCATGAGACGCCGTATGGAGGAGCGTGTTTTTGTCCCCCAGGTTATATCATCAACCAC
AATGACAGCCGTACCTGTGTTGAGTTTGATGATTGCCAGATATGGGGAATTTGTGACCAG
AAGTGTGAAAGCCGACCTGGCCGTCACCTGTGCCACTGTGAAGAAGGGTATATCTTGGAG
CGTGGACAGTATTGCAAAGCTAATGATTCCTTTGGCGAGGCCTCCATTATCTTCTCCAAT
GGTCGGGATTTGTTAATTGGTGATATTCATGGAAGGAGCTTCCGGATCCTAGTGGAGTCT
CAGAATCGTGGAGTGGCCGTGGGTGTGGCTTTCCACTATCACCTGCAAAGAGTTTTTTGG
ACAGACACCGTGCAAAATAAGGTTTTTTCAGTTGACATTAATGGTTTAAATATCCAAGAG
GTTCTCAATGTTTCTGTTGAAACCCCAGAGAACCTGGCTGTGGACTGGGTTAATAATAAA
ATCTATCTAGTGGAAACCAAGGTCAACCGCATAGATATGGTAAATTTGGATGGAAGCTAT
CGGGTTACCCTTATAACTGAAAACTTGGGGCATCCTAGAGGAATTGCCGTGGACCCAACT
GTTGGTTATTTATTTTTCTCAGATTGGGAGAGCCTTTCTGGGGAACCTAAGCTGGAAAGG
GCATTCATGGATGGCAGCAACCGTAAAGACTTGGTGAAAACAAAGCTGGGATGGCCTGCT
GGGGTAACTCTGGATATGATATCGAAGCGTGTTTACTGGGTTGACTCTCGGTTTGATTAC
ATTGAAACTGTAACTTATGATGGAATTCAAAGGAAGACTGTAGTTCATGGAGGCTCCCTC
ATTCCTCATCCCTTTGGAGTAAGCTTATTTGAAGGTCAGGTGTTCTTTACAGATTGGACA
AAGATGGCCGTGCTGAAGGCAAACAAGTTCACAGAGACCAACCCACAAGTGTACTACCAG
GCTTCCCTGAGGCCCTATGGAGTGACTGTTTACCATTCCCTCAGACAGCCCTATGCTACC
AATCCGTGTAAAGATAACAATGGGGGCTGTGAGCAGGTCTGTGTTCTCAGCCACAGAACA
GATAATGATGGTTTGGGTTTCCGTTGCAAGTGCACATTCGGCTTCCAACTGGATACAGAT
GAGCGCCACTGCATTGCTGTTCAGAATTTCCTCATTTTTTCATCCCAAGTTGCTATTCGT
GGGATCCCGTTCACCTTGTCTACCCAGGAAGATGTCATGGTTCCAGTTTCGGGGAATCCT
TCTTTCTTTGTCGGGATTGATTTTGACGCCCAGGACAGCACTATCTTTTTTTCAGATATG
TCAAAACACATGATTTTTAAGCAAAAGATTGATGGCACAGGAAGAGAAATTCTCGCAGCT
AACAGGGTGGAAAATGTTGAAAGTTTGGCTTTTGATTGGATTTCAAAGAATCTCTATTGG
ACAGACTCTCATTACAAGAGTATCAGTGTCATGAGGCTAGCTGATAAAACGAGACGCACA
GTAGTTCAGTATTTAAATAACCCACGGTCGGTGGTAGTTCATCCTTTTGCCGGGTATCTA
TTCTTCACTGATTGGTTCCGTCCTGCTAAAATTATGAGAGCATGGAGTGACGGATCTCAC
CTCTTGCCTGTAATAAACACTACTCTTGGATGGCCCAATGGCTTGGCCATCGATTGGGCT
GCTTCACGATTGTACTGGGTAGATGCCTATTTTGATAAAATTGAGCACAGCACCTTTGAT
GGTTTAGACAGAAGAAGACTGGGCCATATAGAGCAGATGACACATCCGTTTGGACTTGCC
ATCTTTGGAGAGCATTTATTTTTTACTGACTGGAGACTGGGTGCCATTATTCGAGTCAGG
AAAGCAGATGGTGGAGAAATGACAGTTATCCGAAGTGGCATTGCTTACATACTGCATTTG
AAATCGTATGATGTCAACATCCAGACTGGTTCTAACGCCTGTAATCAACCCACGCATCCT
AACGGTGACTGCAGCCACTTCTGCTTCCCGGTGCCAAATTTCCAGCGAGTGTGTGGGTGC
CCTTATGGAATGAGGCTGGCTTCCAATCACTTGACATGCGAGGGGGACCCAACCAATGAA
CCACCCACGGAGCAGTGTGGCTTATTTTCCTTCCCCTGTAAAAATGGCAGATGTGTGCCC
AATTACTATCTCTGTGATGGAGTCGATGATTGTCATGATAACAGTGATGAGCAACTATGT
GGCACACTTAATAATACCTGTTCATCTTCGGCGTTCACCTGTGGCCATGGGGAGTGCATT
CCTGCACACTGGCGCTGTGACAAACGCAACGACTGTGTGGATGGCAGTGATGAGCACAAC
TGCCCCACCCACGCACCTGCTTCCTGCCTTGACACCCAATACACCTGTGATAATCACCAG
TGTATCTCAAAGAACTGGGTCTGTGACACAGACAATGATTGTGGGGATGGATCTGATGAA
AAGAACTGCAATTCGACAGAGACATGCCAACCTAGTCAGTTTAATTGCCCCAATCATCGA
TGTATTGACCTATCGTTTGTCTGTGATGGTGACAAGGATTGTGTTGATGGATCTGATGAG
GTTGGTTGTGTATTAAACTGTACTGCTTCTCAATTCAAGTGTGCCAGTGGGGATAAATGT
ATTGGCGTCACAAATCGTTGTGATGGTGTTTTTGATTGCAGTGACAACTCGGATGAAGCG
GGCTGTCCAACCAGGCCTCCTGGTATGTGCCACTCAGATGAATTTCAGTGCCAAGAAGAT
GGTATCTGCATCCCGAACTTCTGGGAATGTGATGGGCATCCAGACTGCCTCTATGGATCT
GATGAGCACAATGCCTGTGTCCCCAAGACTTGCCCTTCATCATATTTCCACTGTGACAAC
GGAAACTGCATCCACAGGGCATGGCTCTGTGATCGGGACAATGACTGCGGGGATATGAGT
GATGAGAAGGACTGCCCTACTCAGCCCTTTCGCTGTCCTAGTTGGCAATGGCAGTGTCTT
GGCCATAACATCTGTGTGAATCTGAGTGTAGTGTGTGATGGCATCTTTGACTGCCCCAAT
GGGACAGATGAGTCCCCACTTTGCAATGGGAACAGCTGCTCAGATTTCAATGGTGGTTGT
ACTCACGAGTGTGTTCAAGAGCCCTTTGGGGCTAAATGCCTATGTCCATTGGGATTCTTA
CTTGCCAATGATTCTAAGACCTGTGAAGACATAGATGAATGTGATATTCTAGGCTCTTGT
AGCCAGCACTGTTACAATATGAGAGGTTCTTTCCGGTGCTCGTGTGATACAGGCTACATG
TTAGAAAGTGATGGGAGGACTTGCAAAGTTACAGCATCTGAGAGTCTGCTGTTACTTGTG
GCAAGTCAGAACAAAATTATTGCCGACAGTGTCACCTCCCAGGTCCACAATATCTATTCA
TTGGTCGAGAATGGTTCTTACATTGTAGCTGTTGATTTTGATTCAATTAGTGGTCGTATC
TTTTGGTCTGATGCAACTCAGGGTAAAACCTGGAGTGCGTTTCAAAATGGAACGGACAGA
AGAGTGGTATTTGACAGTAGCATCATCTTGACTGAAACTATTGCAATAGATTGGGTAGGT
CGTAATCTTTACTGGACAGACTATGCTCTGGAAACAATTGAAGTCTCCAAAATTGATGGG
AGCCACAGGACTGTGCTGATTAGTAAAAACCTAACAAATCCAAGAGGACTAGCATTAGAT
CCCAGAATGAATGAGCATCTACTGTTCTGGTCTGACTGGGGCCACCACCCTCGCATCGAG
CGAGCCAGCATGGACGGCAGCATGCGCACTGTCATTGTCCAGGACAAGATCTTCTGGCCC
TGCGGCTTAACTATTGACTACCCCAACAGACTGCTCTACTTCATGGACTCCTATCTTGAT
TACATGGACTTTTGCGATTATAATGGACACCATCGGAGACAGGTGATAGCCAGTGATTTG
ATTATACGGCACCCCTATGCCCTAACTCTCTTTGAAGACTCTGTGTACTGGACTGACCGT
GCTACTCGTCGGGTTATGCGAGCCAACAAGTGGCATGGAGGGAACCAGTCAGTTGTAATG
TATAATATTCAATGGCCCCTTGGGATTGTTGCGGTTCATCCTTCGAAACAACCAAATTCC
GTGAATCCATGTGCCTTTTCCCGCTGCAGCCATCTCTGCCTGCTTTCCTCACAGGGGCCT
CATTTTTACTCCTGTGTTTGTCCTTCAGGATGGAGTCTGTCTCCTGATCTCCTGAATTGC
TTGAGAGATGATCAACCTTTCTTAATAACTGTAAGGCAACATATAATTTTTGGAATCTCC
CTTAATCCTGAGGTGAAGAGCAATGATGCTATGGTCCCCATAGCAGGGATACAGAATGGT
TTAGATGTTGAATTTGATGATGCTGAGCAATACATCTATTGGGTTGAAAATCCAGGTGAA
ATTCACAGAGTGAAGACAGATGGCACCAACAGGACAGTATTTGCTTCTATATCTATGGTG
GGGCCTTCTATGAACCTGGCCTTAGATTGGATTTCAAGAAACCTTTATTCTACCAATCCT
AGAACTCAGTCAATCGAGGTTTTGACACTCCACGGAGATATCAGATACAGAAAAACATTG
ATTGCCAATGATGGGACAGCTCTTGGAGTTGGCTTTCCAATTGGCATAACTGTTGATCCT
GCTCGTGGGAAGCTGTACTGGTCAGACCAAGGAACTGACAGTGGGGTTCCTGCCAAGATC
GCCAGTGCTAACATGGATGGCACATCTGTGAAAACTCTCTTTACTGGGAACCTCGAACAC
CTGGAGTGTGTCACTCTTGACATCGAAGAGCAGAAACTCTACTGGGCAGTCACTGGAAGA
GGAGTGATTGAAAGAGGAAACGTGGATGGAACAGATCGGATGATCCTGGTACACCAGCTT
TCCCACCCCTGGGGAATTGCAGTCCATGATTCTTTCCTTTATTATACTGATGAACAGTAT
GAGGTCATTGAAAGAGTTGATAAGGCCACTGGGGCCAACAAAATAGTCTTGAGAGATAAT
GTTCCAAATCTGAGGGGTCTTCAAGTTTATCACAGACGCAATGCCGCCGAATCCTCAAAT
GGCTGTAGCAACAACATGAATGCCTGTCAGCAGATTTGCCTGCCTGTACCAGGAGGATTG
TTTTCCTGCGCCTGTGCCACTGGATTTAAACTCAATCCTGATAATCGGTCCTGCTCTCCA
TATAACTCTTTCATTGTTGTTTCAATGCTGTCTGCAATCAGAGGCTTTAGCTTGGAATTG
TCAGATCATTCAGAAACCATGGTGCCGGTGGCAGGCCAAGGACGAAACGCACTGCATGTG
GATGTGGATGTGTCCTCTGGCTTTATTTATTGGTGTGATTTTAGCAGCTCAGTGGCATCT
GATAATGCGATCCGTAGAATTAAACCAGATGGATCTTCTCTGATGAACATTGTGACACAT
GGAATAGGAGAAAATGGAGTCCGGGGTATTGCAGTGGATTGGGTAGCAGGAAATCTTTAT
TTCACCAATGCCTTTGTTTCTGAAACACTGATAGAAGTTCTGCGGATCAATACTACTTAC
CGCCGTGTTCTTCTTAAAGTCACAGTGGACATGCCTAGGCATATTGTTGTAGATCCCAAG
AACAGATACCTCTTCTGGGCTGACTATGGGCAGAGACCAAAGATTGAGCGTTCTTTCCTT
GACTGTACCAATCGAACAGTGCTTGTGTCAGAGGGCATTGTCACACCACGGGGCTTGGCA
GTGGACCGAAGTGATGGCTACGTTTATTGGGTTGATGATTCTTTAGATATAATTGCAAGG
ATTCGTATCAATGGAGAGAACTCTGAAGTGATTCGTTATGGCAGTCGTTACCCAACTCCT
TATGGCATCACTGTTTTTGAAAATTCTATCATATGGGTAGATAGGAATTTGAAAAAGATC
TTCCAAGCCAGCAAGGAACCAGAGAACACAGAGCCACCCACAGTGATAAGAGACAATATC
AACTGGCTAAGAGATGTGACCATCTTTGACAAGCAAGTCCAGCCCCGGTCACCAGCAGAG
GTCAACAACAACCCTTGCTTGGAAAACAATGGTGGGTGCTCTCATCTCTGCTTTGCTCTG
CCTGGATTGCACACCCCAAAATGTGACTGTGCCTTTGGGACCCTGCAAAGTGATGGCAAG
AATTGTGCCATTTCAACAGAAAATTTCCTCATCTTTGCCTTGTCTAATTCCTTGAGAAGC
TTACACTTGGACCCTGAAAACCATAGCCCACCTTTCCAAACAATAAATGTGGAAAGAACT
GTCATGTCTCTAGACTATGACAGTGTAAGTGATAGAATCTACTTCACACAAAATTTAGCC
TCTGGAGTTGGACAGATTTCCTATGCCACCCTGTCTTCAGGGATCCATACTCCAACTGTC
ATTGCTTCAGGTATAGGGACTGCTGATGGCATTGCCTTTGACTGGATTACTAGAAGAATT
TATTACAGTGACTACCTCAACCAGATGATTAATTCCATGGCTGAAGATGGGTCTAACCGC
ACTGTGATAGCCCGCGTTCCAAAACCAAGAGCAATTGTGTTAGATCCCTGCCAAGGGTAC
CTGTACTGGGCTGACTGGGATACACATGCCAAAATCGAGAGAGCCACATTGGGAGGAAAC
TTCCGGGTACCCATTGTGAACAGCAGTCTGGTCATGCCCAGTGGGCTGACTCTGGACTAT
GAAGAGGACCTTCTCTACTGGGTGGATGCTAGTCTGCAGAGGATTGAACGCAGCACTCTG
ACGGGCGTGGATCGTGAAGTCATTGTCAATGCAGCCGTTCATGCTTTTGGCTTGACTCTC
TATGGCCAGTATATTTACTGGACTGACTTGTACACACAAAGAATTTACCGAGCTAACAAA
TATGACGGGTCAGGTCAGATTGCAATGACCACAAATTTGCTCTCCCAGCCCAGGGGAATC
AACACTGTTGTGAAGAACCAGAAACAACAGTGTAACAATCCTTGTGAACAGTTTAATGGG
GGCTGCAGCCATATCTGTGCACCAGGTCCAAATGGTGCCGAGTGCCAGTGTCCACATGAG
GGCAACTGGTATTTGGCCAACAACAGGAAGCACTGCATTGTGGACAATGGTGAACGATGT
GGTGCATCTTCCTTCACCTGCTCCAATGGGCGCTGCATCTCGGAAGAGTGGAAGTGTGAT
AATGACAACGACTGTGGGGATGGCAGTGATGAGATGGAAAGTGTCTGTGCACTTCACACC
TGCTCACCGACAGCCTTCACCTGTGCCAATGGGCGATGTGTCCAATACTCTTACCGCTGT
GATTACTACAATGACTGTGGTGATGGCAGTGATGAGGCAGGGTGCCTGTTCAGGGACTGC
AATGCCACCACGGAGTTTATGTGCAATAACAGAAGGTGCATACCTCGTGAGTTTATCTGC
AATGGTGTAGACAACTGCCATGATAATAACACTTCAGATGAGAAAAATTGCCCTGATCGC
ACTTGCCAGTCTGGATACACAAAATGTCATAATTCAAATATTTGTATTCCTCGCGTTTAT
TTGTGTGACGGAGACAATGACTGTGGAGATAACAGTGATGAAAACCCTACTTATTGCACC
ACTCACACATGCAGCAGCAGTGAGTTCCAATGCGCATCTGGGCGCTGTATTCCTCAACAT
TGGTATTGTGATCAAGAAACAGATTGTTTTGATGCCTCTGATGAACCTGCCTCTTGTGGT
CACTCTGAGCGAACATGCCTAGCTGATGAGTTCAAGTGTGATGGTGGGAGGTGCATCCCA
AGCGAATGGATCTGTGACGGTGATAATGACTGTGGGGATATGAGTGACGAGGATAAAAGG
CACCAGTGTCAGAATCAAAACTGCTCGGATTCCGAGTTTCTCTGTGTAAATGACAGACCT
CCGGACAGGAGGTGCATTCCCCAGTCTTGGGTCTGTGATGGCGATGTGGATTGTACTGAC
GGCTACGATGAGAATCAGAATTGCACCAGGAGAACTTGCTCTGAAAATGAATTCACCTGT
GGTTACGGACTGTGTATCCCAAAGATATTCAGGTGTGACCGGCACAATGACTGTGGTGAC
TATAGCGACGAGAGGGGCTGCTTATACCAGACTTGCCAACAGAATCAGTTTACCTGTCAG
AACGGGCGCTGCATTAGTAAAACCTTCGTCTGTGATGAGGATAATGACTGTGGAGACGGA
TCTGATGAGCTGATGCACCTGTGCCACACCCCAGAACCCACGTGTCCACCTCACGAGTTC
AAGTGTGACAATGGGCGCTGCATCGAGATGATGAAACTCTGCAACCACCTAGATGACTGT
TTGGACAACAGCGATGAGAAAGGCTGTGGCATTAATGAATGCCATGACCCTTCAATCAGT
GGCTGCGATCACAACTGCACAGACACCTTAACCAGTTTCTATTGTTCCTGTCGTCCTGGT
TACAAGCTCATGTCTGACAAGCGGACTTGTGTTGATATTGATGAATGCACAGAGATGCCT
TTTGTCTGTAGCCAGAAGTGTGAGAATGTAATAGGCTCCTACATCTGTAAGTGTGCCCCA
GGCTACCTCCGAGAACCAGATGGAAAGACCTGCCGGCAAAACAGTAACATCGAACCCTAT
CTCATTTTTAGCAACCGTTACTATTTGAGAAATTTAACTATAGATGGCTATTTTTACTCC
CTCATCTTGGAAGGACTGGACAATGTTGTGGCATTAGATTTTGACCGAGTAGAGAAGAGA
TTGTATTGGATTGATACACAGAGGCAAGTCATTGAGAGAATGTTTCTGAATAAGACAAAC
AAGGAGACAATCATAAACCACAGACTACCAGCTGCAGAAAGTCTGGCTGTAGACTGGGTT
TCCAGAAAGCTCTACTGGTTGGATGCCCGCCTGGATGGCCTCTTTGTCTCTGACCTCAAT
GGTGGACACCGCCGCATGCTGGCCCAGCACTGTGTGGATGCCAACAACACCTTCTGCTTT
GATAATCCCAGAGGACTTGCCCTTCACCCTCAATATGGGTACCTCTACTGGGCAGACTGG
GGTCACCGCGCATACATTGGGAGAGTAGGCATGGATGGAACCAACAAGTCTGTGATAATC
TCCACCAAGTTAGAGTGGCCTAATGGCATCACCATTGATTACACCAATGATCTACTCTAC
TGGGCAGATGCCCACCTGGGTTACATAGAGTACTCTGATTTGGAGGGCCACCATCGACAC
ACGGTGTATGATGGGGCACTGCCTCACCCTTTCGCTATTACCATTTTTGAAGACACTATT
TATTGGACAGATTGGAATACAAGGACAGTGGAAAAGGGAAACAAATATGATGGATCAAAT
AGACAGACACTGGTGAACACAACACACAGACCATTTGACATCCATGTGTACCATCCATAT
AGGCAGCCCATTGTGAGCAATCCCTGTGGTACCAACAATGGTGGCTGTTCTCATCTCTGC
CTCATCAAGCCAGGAGGAAAAGGGTTCACTTGCGAGTGTCCAGATGACTTCCGCACCCTT
CAACTGAGTGGCAGCACCTACTGCATGCCCATGTGCTCCAGCACCCAGTTCCTGTGCGCT
AACAATGAAAAGTGCATTCCTATCTGGTGGAAATGTGATGGACAGAAAGACTGCTCAGAT
GGCTCTGATGAACTGGCCCTTTGCCCGCAGCGCTTCTGCCGACTGGGACAGTTCCAGTGC
AGTGACGGCAACTGCACCAGCCCGCAGACTTTATGCAATGCTCACCAAAATTGCCCTGAT
GGGTCTGATGAAGACCGTCTTCTTTGTGAGAATCACCACTGTGACTCCAATGAATGGCAG
TGCGCCAACAAACGTTGCATCCCAGAATCCTGGCAGTGTGACACATTTAACGACTGTGAG
GATAACTCAGATGAAGACAGTTCCCACTGTGCCAGCAGGACCTGCCGGCCGGGCCAGTTT
CGGTGTGCTAATGGCCGCTGCATCCCGCAGGCCTGGAAGTGTGATGTGGATAATGATTGT
GGAGACCACTCGGATGAGCCCATTGAAGAATGCATGAGCTCTGCCCATCTCTGTGACAAC
TTCACAGAATTCAGCTGCAAAACAAATTACCGCTGCATCCCAAAGTGGGCCGTGTGCAAT
GGTGTAGATGACTGCAGGGACAACAGTGATGAGCAAGGCTGTGAGGAGAGGACATGCCAT
CCTGTGGGGGATTTCCGCTGTAAAAATCACCACTGCATCCCTCTTCGTTGGCAGTGTGAT
GGGCAAAATGACTGTGGAGATAACTCAGATGAGGAAAACTGTGCTCCCCGGGAGTGCACA
GAGAGCGAGTTTCGATGTGTCAATCAGCAGTGCATTCCCTCGCGATGGATCTGTGACCAT
TACAACGACTGTGGGGACAACTCAGATGAACGGGACTGTGAGATGAGGACCTGCCATCCT
GAATATTTTCAGTGTACAAGTGGACATTGTGTACACAGTGAACTGAAATGCGATGGATCC
GCTGACTGTTTGGATGCGTCTGATGAAGCTGATTGTCCCACACGCTTTCCTGATGGTGCA
TACTGCCAGGCTACTATGTTCGAATGCAAAAACCATGTTTGTATCCCGCCATATTGGAAA
TGTGATGGCGATGATGACTGTGGCGATGGTTCAGATGAAGAACTTCACCTGTGCTTGGAT
GTTCCCTGTAATTCACCAAACCGTTTCCGGTGTGACAACAATCGCTGCATTTATAGTCAT
GAGGTGTGCAATGGTGTGGATGACTGTGGAGATGGAACTGATGAGACAGAGGAGCACTGT
AGAAAACCGACCCCTAAACCTTGTACAGAATATGAATATAAGTGTGGCAATGGGCATTGC
ATTCCACATGACAATGTGTGTGATGATGCCGATGACTGTGGTGACTGGTCCGATGAACTG
GGTTGCAATAAAGGAAAAGAAAGAACATGTGCTGAAAATATATGCGAGCAAAATTGTACC
CAATTAAATGAAGGAGGATTTATCTGCTCCTGTACAGCTGGGTTCGAAACCAATGTTTTT
GACAGAACCTCCTGTCTAGATATCAATGAATGTGAACAATTTGGGACTTGTCCCCAGCAC
TGCAGAAATACCAAAGGAAGTTATGAGTGTGTCTGTGCTGATGGCTTCACGTCTATGAGT
GACCGCCCTGGAAAACGATGTGCAGCTGAGGGTAGCTCTCCTTTGTTGCTACTGCCTGAC
AATGTCCGAATTCGAAAATATAATCTCTCATCTGAGAGGTTCTCAGAGTATCTTCAAGAT
GAGGAATATATCCAAGCTGTTGATTATGATTGGGATCCCAAGGACATAGGCCTCAGTGTT
GTGTATTACACTGTGCGAGGGGAGGGCTCTAGGTTTGGTGCTATCAAACGTGCCTACATC
CCCAACTTTGAATCCGGCCGCAATAATCTTGTGCAGGAAGTTGACCTGAAACTGAAATAC
GTAATGCAGCCAGATGGAATAGCAGTGGACTGGGTTGGAAGGCATATTTACTGGTCAGAT
GTCAAGAATAAACGCATTGAGGTGGCTAAACTTGATGGAAGGTACAGAAAGTGGCTGATT
TCCACTGACCTGGACCAACCAGCTGCTATTGCTGTGAATCCCAAACTAGGGCTTATGTTC
TGGACTGACTGGGGAAAGGAACCTAAAATCGAGTCTGCCTGGATGAATGGAGAGGACCGC
AACATCCTGGTTTTCGAGGACCTTGGTTGGCCAACTGGCCTTTCTATCGATTATTTGAAC
AATGACCGAATCTACTGGAGTGACTTCAAGGAGGACGTTATTGAAACCATAAAATATGAT
GGGACTGATAGGAGAGTCATTGCAAAGGAAGCAATGAACCCTTACAGCCTGGACATCTTT
GAAGACCAGTTATACTGGATATCTAAGGAAAAGGGAGAAGTATGGAAACAAAATAAATTT
GGGCAAGGAAAGAAAGAGAAAACGCTGGTAGTGAACCCTTGGCTCACTCAAGTTCGAATC
TTTCATCAACTCAGATACAATAAGTCAGTGCCCAACCTTTGCAAACAGATCTGCAGCCAC
CTCTGCCTTCTGAGACCTGGAGGATACAGCTGTGCCTGTCCCCAAGGCTCCAGCTTTATA
GAGGGGAGCACCACTGAGTGTGATGCAGCCATCGAACTGCCTATCAACCTGCCCCCCCCA
TGCAGGTGCATGCACGGAGGAAATTGCTATTTTGATGAGACTGACCTCCCCAAATGCAAG
TGTCCTAGCGGCTACACCGGAAAATATTGTGAAATGGCGTTTTCAAAAGGCATCTCTCCA
GGAACAACCGCAGTAGCTGTGCTGTTGACAATCCTCTTGATCGTCGTAATTGGAGCTCTG
GCAATTGCAGGATTCTTCCACTATAGAAGGACCGGCTCCCTTTTGCCTGCTCTGCCCAAG
CTGCCAAGCTTAAGCAGTCTCGTCAAGCCCTCTGAAAATGGGAATGGGGTGACCTTCAGA
TCAGGGGCAGATCTTAACATGGATATTGGAGTGTCTGGTTTTGGACCTGAGACTGCTATT
GACAGGTCAATGGCAATGAGTGAAGACTTTGTCATGGAAATGGGGAAGCAGCCCATAATA
TTTGAAAACCCAATGTACTCAGCCAGAGACAGTGCTGTCAAAGTGGTTCAGCCAATCCAG
GTGACTGTATCTGAAAATGTGGATAATAAGAATTATGGAAGTCCCATAAACCCTTCTGAG
ATAGTTCCAGAGACAAACCCAACTTCACCAGCTGCTGATGGAACTCAGGTGACAAAATGG
AATCTCTTCAAACGAAAATCTAAACAAACTACCAACTTTGAAAATCCAATCTATGCACAG
ATGGAGAACGAGCAAAAGGAAAGTGTTGCTGCGACACCACCTCCATCACCTTCGCTCCCT
GCTAAGCCTAAGCCTCCTTCGAGAAGAGACCCAACTCCAACCTATTCTGCAACAGAAGAC
ACTTTTAAAGACACCGCAAATCTTGTTAAAGAAGACTCTGAAGTATAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00008</identifier>
        <name>EGF</name>
      </pfam>
      <pfam>
        <identifier>PF07645</identifier>
        <name>EGF_CA</name>
      </pfam>
      <pfam>
        <identifier>PF00057</identifier>
        <name>Ldl_recept_a</name>
      </pfam>
      <pfam>
        <identifier>PF00058</identifier>
        <name>Ldl_recept_b</name>
      </pfam>
      <pfam>
        <identifier>PF07974</identifier>
        <name>EGF_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cell</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cation binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="11">
      <id>BE0002126</id>
      <name>Insulin-like growth factor-binding protein 7</name>
      <organism>Human</organism>
      <actions/>
      <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
      <known-action>unknown</known-action>
      <polypeptide id="Q16270" source="Swiss-Prot">
    <name>Insulin-like growth factor-binding protein 7</name>
    <general-function/>
    <specific-function>Binds IGF-I and IGF-II with a relatively low affinity. Stimulates prostacyclin (PGI2) production</specific-function>
    <gene-name>IGFBP7</gene-name>
    <locus>4q12</locus>
    <cellular-location>Secreted protein</cellular-location>
    <transmembrane-regions>None</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>7.94</theoretical-pi>
    <molecular-weight>29131.0</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5476</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IGFBP7</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GeneCards</resource>
        <identifier>IGFBP7</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L19182</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>307151</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q16270</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IBP7_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IBP- 7</synonym>
      <synonym>IGF-binding protein 7</synonym>
      <synonym>IGFBP-7</synonym>
      <synonym>IGFBP-rP1</synonym>
      <synonym>Insulin-like growth factor-binding protein 7 precursor</synonym>
      <synonym>MAC25 protein</synonym>
      <synonym>PGI2-stimulating factor</synonym>
      <synonym>Prostacyclin-stimulating factor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;Insulin-like growth factor-binding protein 7
MERPSLRALLLGAAGLLLLLLPLSSSSSSDTCGPCEPASCPPLPPLGCLLGETRDACGCC
PMCARGEGEPCGGGGAGRGYCAPGMECVKSRKRRKGKAGAAAGGPGVSGVCVCKSRYPVC
GSDGTTYPSGCQLRAASQRAESRGEKAITQVSKGTCEQGPSIVTPPKDIWNVTGAQVYLS
CEVIGIPTPVLIWNKVKRGHYGVQRTELLPGDRDNLAIQTRGGPEKHEVTGWVLVSPLSK
EDAGEYECHASNSQGQASASAKITVVDALHEIPVKKGEGAEL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;834 bp
ATGGAGCGCGCGTCGCTGCGCGCCCTGCTCTTCGGCCCCGCTGGGCTGCTGCTCCTGCTC
CTGCCCCTCTCCTCTTCCTCCTCTTCGGACACCTGCGGCCCCTGCGAGCCGGCCTCCTGC
CCGCCCCTGCCCCCGCTGGGCTGCCTGCTGGGCGAGACCCGCGACGCGTGCGGCTGCTGC
CCTATGTGCGCCCGCGGCGAGGGCGAGCCGTGCGGGGGTGGCGGCGCCGGCAGGGGGTAC
TGCGCGCCGGGCATGGAGTGCGTGAAGAGCCGCAAGAGGCGGAGGGGTAAAGCCGGGGCA
GCAGCCGGCGGTCCGGGTGTAAGCGGCGTGTGCGTGTGCAAGAGCCGCTACCCGGTGTGC
GGCAGCGACGGCACCACCTACCCGAGCGGCTGCCAGCTGCGCGCCGCCAGCCAGAGGGCC
GAGAGCCGCGGGGAGAAGGCCATCACCCAGGTCAGCAAGGGCACCTGCGAGCAAGGTCCT
TCCATAGTGACGCCCCCCAAGGACATCTGGAATGTCACTGGTGCCCAGGTGTACTTGAGC
TGTGAGGTCATCGGAATCCCGACACCTGTCCTCATCTGGAACAAGGTAAAAAGGGGTCAC
TATGGAGTTCAAAGGACAGAACTCCTGCCTGGTGACCGGGACAACCTGGCCATTCAGACC
CGGGGTGGCCCAGAAAAGCATGAAGTAACTGGCTGGGTGCTGGTATCTCCTCTAAGTAAG
GAAGATGCTGGAGAATATGAGTGCCATGCATCCAATTCCCAAGGACAGGCTTCAGCATCA
GCAAAAATTACAGTGGTTGATGCCTTACATGAAATAGCCAGTGAAAAAAGGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07679</identifier>
        <name>I-set</name>
      </pfam>
      <pfam>
        <identifier>PF07648</identifier>
        <name>Kazal_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>growth factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin-like growth factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of biological process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell growth</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="12">
      <id>BE0002127</id>
      <name>Synaptotagmin-like protein 4</name>
      <organism>Human</organism>
      <actions/>
      <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
      <known-action>unknown</known-action>
      <polypeptide id="Q96C24" source="Swiss-Prot">
    <name>Synaptotagmin-like protein 4</name>
    <general-function/>
    <specific-function>Modulates exocytosis of dense-core granules and secretion of hormones in the pancreas and the pituitary. Interacts with vesicles containing negatively charged phospholipids in a Ca(2+)-independent manner</specific-function>
    <gene-name>SYTL4</gene-name>
    <locus>-</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>None</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.42</theoretical-pi>
    <molecular-weight>76010.0</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:15588</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>SYTL4</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GeneCards</resource>
        <identifier>SYTL4</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AK094110</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>21753104</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q96C24</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>SYTL4_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Exophilin-2</synonym>
      <synonym>Granuphilin</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;Synaptotagmin-like protein 4
MSELLDLSFLSEEEKDLILSVLQRDEEVRKADEKRIRRLKNELLEIKRKGAKRGSQHYSD
RTCARCQESLGRLSPKTNTCRGCNHLVCRDCRIQESNGTWRCKVCAKEIELKKATGDWFY
DQKVNRFAYRTGSEIIRMSLRHKPAVSKRETVGQSLLHQTQMGDIWPGRKIIQERQKEPS
VLFEVPKLKSGKSALEAESESLDSFTADSDSTSRRDSLDKSGLFPEWKKMSAPKSQVEKE
TQPGGQNVVFVDEGEMIFKKNTRKILRPSEYTKSVIDLRPEDVVHESGSLGDRSKSVPGL
NVDMEEEEEEEDIDHLVKLHRQKLARSSMQSGSSMSTIGSMMSIYSEAGDFGNIFVTGRI
AFSLKYEQQTQSLVVHVKECHQLAYADEAKKRSNPYVKTYLLPDKSRQGKRKTSIKRDTV
NPLYDETLRYEIPESLLAQRTLQFSVWHHGRFGRNTFLGEAEIQMDSWKLDKKLDHCLPL
HGKISAESPTGLPSHKGELVVSLKYIPASKTPVGGDRKKSKGGEGGELQVWIKEAKNLTA
AKAGGTSDSFVKGYLLPMRNKASKRKTPVMKKTLNPHYNHTFVYNGVRLEDLQHMCLELT
VWDREPLASNDFLGGVRLGVGTGISNGEVVDWMDSTGEEVSLWQKMRQYPGSWAEGTLQL
RSSMAKQKLGL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;2016 bp
ATGTCGGAGTTACTGGACCTTTCTTTTCTGTCTGAGGAGGAAAAGGATTTGATTCTCAGT
GTTCTACAGCGAGATGAAGAGGTCCGGAAAGCAGATGAGAAAAGGATTAGGCGACTAAAG
AATGAGTTACTGGAGATAAAAAGGAAAGGGGCCAAGAGGGGCAGCCAACACTACAGTGAT
CGGACCTGTGCCCGGTGCCAGGAGAGCCTGGGCCGTTTGAGTCCCAAAACCAATACTTGT
CGGGGTTGTAATCACCTGGTGTGTCGGGACTGCCGCATACAGGAAAGCAATGGTACCTGG
AGGTGCAAGGTGTGCGCCAAGGAAATAGAGTTGAAGAAAGCAACTGGGGACTGGTTTTAT
GACCAGAAAGTGAATCGCTTTGCTTACCGCACAGGTAGTGAGATAATCAGGATGTCCCTG
CGCCACAAACCTGCAGTGAGTAAAAGAGAGACAGTGGGACAGTCCCTCCTTCATCAGGCA
CAGATGGGTGACATCTGGCCAGGAAGAAAGATCATTCAGGAGCGGCAGAAGGAGCCCAGT
GTGCTATTTGAAGTGCCAAAGCTGAAAAGTGGAAAGAGTGCATTGGAAGCTGAGAGTGAG
AGTCTGGATAGCTTCACAGCTGACTCGGATAGCACCTCCAGGAGAGACTCTCTGGATAAA
TCTGGCCTCTTTCCAGAATGGAAGAAGATGTCTGCTCCCAAATCTCAAGTAGAAAAGGAA
ACTCAGCCTGGAGGTCAAAATGTGGTATTTGTGGATGAGGGTGAGATGATATTTAAGAAG
AACACCAGAAAAATCCTCAGGCCTTCAGAGTACACTAAATCTGTGATAGATCTTCGCCCA
GAAGATGTGGTACATGAAGGTGGCTCCTTGGGAGACAGAAGCAAATCCGTCCCAGGCCTC
AATGTGGATATGGAAGAGGAAGAAGAAGAAGAAGACATTGACCACCTAGTGAAGTTACAT
CGCCAGAAGCTAGCCAGAAGCAGCATGCAAAGTGGCTCCTCCATGAGTACGATCGGCAGC
ATGATGAGCATCTACAGTGAAGCTGGTGATTTCGGGAACATCTTTGTGACTGGCAGGATT
GCCTTTTCCCTGAAGTATGAGCAGCAAACCCAGAGTCTGGTTGTCCATGTGAAGGAGTGC
CATCAGCTGGCCTATGCTGATGAAGCCAAGAAGCGCTCTAACCCATATGTGAAGACTTAC
CTTCTGCCTGACAAGTCCCGCCAAGGAAAAAGAAAAACCAGCATCAAGCGGGACACTGTT
AATCCACTATATGATGAGACGCTGAGGTATGAGATCCCAGAATCTCTCCTGGCCCAGAGG
ACCCTGCAGTTCTCAGTTTGGCATCATGGTCGTTTTGGCAGAAACACTTTCCTTGGAGAG
GCAGAGATCCAGATGGATTCCTGGAAGCTTGATAAGAAACTGGATCATTGCCTCCCTTTA
CATGGAAAGATCAGTGCTGAGTCCCCGACTGGCTTGCCATCACACAAAGGCGAGTTGGTG
GTTTCATTGAAATACATCCCAGCCTCCAAAACCCCTGTTGGAGGTGACCGGAAAAAGAGT
AAAGGTGGGGAAGGGGGAGAGCTCCAGGTGTGGATCAAAGAAGCCAAGAACTTGACGGCT
GCCAAAGCAGGAGGGACTTCAGACAGCTTTGTCAAGGGATACCTCCTTCCCATGAGGAAC
AAGGCCAGTAAACGTAAAACTCCTGTGATGAAGAAGACCCTGAATCCTCACTACAACCAT
ACATTTGTCTACAATGGTGTGAGGCTGGAAGATCTACAGCATATGTGCCTGGAACTGACT
GTGTGGGACCGGGAGCCCCTGGCCAGCAATGACTTCCTGGGAGGGGTCAGGCTGGGTGTT
GGCACTGGGATCAGTAATGGGGAAGTGGTGGACTGGATGGACTCGACTGGGGAAGAAGTG
AGCCTGTGGCAGAAGATGCGACAGTACCCAGGGTCTTGGGCAGAAGGGACTCTGCAGCTC
CGTTCCTCAATGGCCAAGCAGAAGCTGGGTTTATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00168</identifier>
        <name>C2</name>
      </pfam>
      <pfam>
        <identifier>PF02318</identifier>
        <name>RPH3A_effector</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasmic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasmic membrane-bound vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>coated vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>clathrin-coated vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synaptic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>organelle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>ubiquitin ligase complex</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ligase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cation binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transition metal ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transporter activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ligase activity, forming carbon-nitrogen bonds</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>acid-amino acid ligase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>catalytic activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ubiquitin-protein ligase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>GTPase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>zinc ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>small GTPase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>Rab GTPase binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intracellular protein transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>physiological process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular physiological process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ubiquitin cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>macromolecule metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein ubiquitination</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>biopolymer metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>biopolymer modification</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme>
      <id>BE0002433</id>
      <name>Cytochrome P450 1A2</name>
      <organism>Human</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references># Flockhart DA. "Drug Interactions: Cytochrome P450 Drug Interaction Table":http://medicine.iupui.edu/clinpharm/ddis/table.asp. Indiana University School of Medicine (2007). Accessed May 28, 2010.</references>
      <known-action>unknown</known-action>
      <polypeptide id="P05177" source="Swiss-Prot">
    <name>Cytochrome P450 1A2</name>
    <general-function>Involved in monooxygenase activity</general-function>
    <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen</specific-function>
    <gene-name>CYP1A2</gene-name>
    <locus>15q24</locus>
    <cellular-location>Endoplasmic reticulum</cellular-location>
    <transmembrane-regions>None</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.43</theoretical-pi>
    <molecular-weight>58295.0</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2596</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CYP1A2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>Z00036</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05177</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CP1A2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CYPIA2</synonym>
      <synonym>EC 1.14.14.1</synonym>
      <synonym>P(3)450</synonym>
      <synonym>P450 4</synonym>
      <synonym>P450-P3</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;1548 bp
ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
CACGCCCGCTGTGAACATGTCCAGGCGCGGCGCTTCTCCATCAATTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00067</identifier>
        <name>p450</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>function</category>
        <description>transition metal ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>tetrapyrrole binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>catalytic activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cation binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>generation of precursor metabolites and energy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>electron transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>physiological process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>metabolism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular metabolism</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>